WO2008075152A1 - 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension - Google Patents

1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension Download PDF

Info

Publication number
WO2008075152A1
WO2008075152A1 PCT/IB2007/003831 IB2007003831W WO2008075152A1 WO 2008075152 A1 WO2008075152 A1 WO 2008075152A1 IB 2007003831 W IB2007003831 W IB 2007003831W WO 2008075152 A1 WO2008075152 A1 WO 2008075152A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ono
cio
alkoxy
aryl
Prior art date
Application number
PCT/IB2007/003831
Other languages
French (fr)
Inventor
Wesley Kwan Mung Chong
Seiji Nukui
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2008075152A1 publication Critical patent/WO2008075152A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • the present invention relates to compounds of formula I:
  • R A through R E are as defined herein. Methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for inhibiting carbonic anhydrase, and thereby lowering intraocular pressure and treating glaucoma are also provided.
  • Glaucoma is optic nerve damage, often associated with increased intraocular pressure (lOP), that leads to progressive, irreversible loss of vision. Almost 3 million people in the United States and 14 million people worldwide have glaucoma; this is the third leading cause of blindness worldwide. Glaucoma occurs when an imbalance in production and drainage of fluid in the eye (aqueous humor) increases eye pressure to unhealthy levels.
  • lOP intraocular pressure
  • elevated IOP can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-adrenergic antagonists, ⁇ -adrenergic agonists, cholinergic agents, prostaglandin analogs or carbonic anhydrase inhibitors.
  • drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-adrenergic antagonists, ⁇ -adrenergic agonists, cholinergic agents, prostaglandin analogs or carbonic anhydrase inhibitors.
  • Topical beta-adrenergic antagonists show serious pulmonary side effects, depression, fatigue, confusion, impotence, hair loss, heart failure and bradycardia.
  • Topical ⁇ -adrenergic agonists have a fairly high incidence of allergic or toxic reactions; topical cholinergic agents (miotics) can cause visual side effects
  • topical prostaglandin analogs (bimatoprost, latanoprost, travoprost and unoprostone) used in the treatment of glaucoma can produce ocular side effects, such as increased pigmentation of the iris ocular irritation, conjunctival hyperaemia, ulceris, uveitis and macular edema (Martindale, Thirty-third edition, p 1445)
  • WO2006/052899 discloses novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions, for treating ophthalmic disorders comprising at least one nitrosated and/or nitrosylated compound, and optionally at least one nitric oxide donor and/or at least one therapeutic agent selected from the group consisting of an ⁇ -adrenerg ⁇ c receptor agonist, an ACE inhibitor an antimicrobial a ⁇ -adrenergic antagonist, a carbonic anhydrase inhibitor, a non-steroidal anti-inflammatory drug, a prostaglandin, a COX-2 inhibitor and a steroid
  • the present invention relates to new carbonic anhydrase inhibitor derivatives More particularly, the present invention relates to unique triazole-benzenesulfonamides, pharmaceutical compositions containing them, and their use as drugs for treating glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies
  • An object of the present invention to provide new derivatives of carbonic anhydrase inhibitors able not only to eliminate or at least reduce the side effects associated with the parent compounds, but also to improve pharmacological activity It has been surprisingly found that nitrooxyde ⁇ vatives of carbonic anhydrase inhibitors have a significantly improved overall profile as compared to native carbonic anhydrase inhibitors both in terms of wider pharmacological activity, enhanced tolerability and long- acting ocular hypotensive activity In particular, it has been recognized that the carbonic anhydrase inhibitor nitroderivatives of the present invention can be employed for treating ocular hypertension and preventing glaucoma Moreover, they have been found to be effective for the treatment of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies.
  • the compounds of the present invention are indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty.
  • An object of the present invention is a method for treating eye disorders, in particular glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor able to release nitric oxide.
  • a carbonic anhydrase inhibitor is a compound having an inhibition constant (Kj) against the isoenzyme CAM in the range of 0,01-200 nM. The carbonic anhydrase activity is measured according to the test on carbonic anhydrase inhibition as reported below.
  • a carbonic anhydrase inhibitor able to release nitric oxide is a compound having an EC 50 value in the range of 1-50 ⁇ M, in vasorelaxation.
  • the compounds of the present invention are triazoles which inhibit carbonic anhydrase activity, and are thereby useful for lowering intraocular pressure and treating glaucoma, without producing significant systemic side effects when delivered topically to the eye.
  • R 1 is H, (C r C 10 )alkyl, -OR 5 , -C(O)R 5 , -C(O)OR 5 , or -C(O)C-R .
  • R 3 is H or halo;
  • each R A , R B , R c , R D , and R E is independently H, (C r C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, -OR 5 , or -C(O)R 5 ;
  • each R 5 is independently H, -OH, - NO 2 , -ONO 2 , (d-C 6 )alkyl, (C 3 -Ci 0 )cycloalkyl, (C r C 6 )alkoxy, (C 3 -C 10 )cycl
  • R 2 is NH 2 , N , or -N- C-CH 3
  • R 3 is selected from Br, Cl, F, and I.
  • each R A , R B , R c , R D , and R E is independently H or (C r C 6 )alkyl.
  • R 1 is H, (C r C 10 )alkyl, -OR 5 , -C(O)R 5 , -C(O)OR 5 , or -C(O)C-R .
  • R 1 is H, (C r C 10 )alkyl, -OR 5 , -C(O)R 5 , -C(O)OR 5 , or -C(O)C-R 9 .
  • R 2 is (Cr C 6 )alkyl or NR 6 R 7 ; each R 5 is independently H, -OH, -NO 2 , -ONO 2 , (C r C 6 )alkyl, (C 3 - C 10 )cycioalkyl, (C r C 6 )a!koxy, (C 3 -Ci 0 )cycloalkoxy, (C 6 -C- ⁇ o)aryl, or (C 6 -Cio)heteroaryl, wherein each of said (d-C 6 )alkyl, (C 3 -C 10 )cycloalkyl, (C r C 6 )alkoxy, (C 3 -C 10 )cycloalkoxy, (C 6
  • R 10 is H or C"R13 ;
  • R 11 is H, (C r C 10 )alkyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , or o -C(O)C-R 13 .
  • each R i2 is independently H, -OH, -NO 2 , -ONO 2 , (C r C 6 )alkyl, (C 3 - Cio)cycloalkyl, (C r C 6 )alkoxy, (C 3 -Ci 0 )cycloalkoxy, (C 6 -Ci 0 )aryl, or (C 6 -Ci 0 )heteroaryl, wherein each of said (C r C 6 )alkyl, (C3-Cio)cycloalkyl, (Ci-C 6 )alkoxy, (C 3 -Cio)cycloalkoxy, (C6-Cio)aryl, and (C 6 -Cio)heteroaryl moieties of said R 12 groups is optionally substituted by one or more R 13 moieties; R 13 is independently -NO 2 , -ONO 2 , (C r C 6 )alkyl, (C 2 -
  • Cio)heterocycloalkyl, (C 6 -Ci O )aryl, and (C 6 -C-io)heteroaryl moieties of said R 9 groups are optionally substituted by -NO 2 , -ONO 2 , [(Ci-Ci 0 )alkoxy]NO 2 , [(C 1 -C 10 )alkoxy]ONO 2 , [(C 1 - Ce)alkyl]ON ⁇ 2 , or [(CrC 6 )alkyl]NO 2 ; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
  • R 10 is H or C"R13 ;
  • R 11 is H, (C r C 10 )alkyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , or
  • each R i2 is j nde p end ently H, -OH, -NO 2 , -ONO 2 , (C r C 6 )alkyl, (C 3 - C 10 )cycloalkyl, (C r C 6 )alkoxy, (C 3 -C 10 )cycloalkoxy, (C 6 -C 10 )aryl, or (C 6 -Ci 0 )heteroaryl, wherein each of said (Ci-C 6 )alkyl, (C 3 -Cio)cycloalkyl, (CrC 6 )alkoxy, (C 3 -Cio)cycloalkoxy, (C 6 -Cio)aryl, and (C 6 -Cio)heteroaryl moieties of said R 12 groups is optionally substituted by one or more R 13 moieties; R 13 is independently -NO 2 , -ONO
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of one or more compounds according to the above disclosure.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to the above disclosure in a suitable form for topical administration.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a. compound according to the above disclosure for the treatment of glaucoma and ocular hypertension.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to the above disclosure, wherein the compound of formula I is administered as a solution, suspension or emulsion in an ophthalmically acceptable vehicle.
  • a method for treating glaucoma or ocular hypertension comprising contacting an effective intraocular pressure reducing amount of a pharmaceutical composition according to the above disclosure with the eye in order to reduce eye pressure and to maintain the pressure at a reduced level.
  • a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide and/or where the eye disorder is selected from glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies.
  • a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide wherein the carbonic anhydrase inhibitor is a compound having an inhibition constant (Kj) against the isoenzyme CAII in the range of 0.01 to 200 nM.
  • Kj inhibition constant
  • a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide wherein the carbonic anhydrase inhibitor able to release nitric oxide is a compound having an EC 50 value in the range of 1 to 50 ⁇ M.
  • a method for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies comprising administering one or more compounds or pharmaceutical compositions according to the above disclosure.
  • one or more compounds as disclosed above for use as a medicament, or for the preparation of a medicament for treating glaucoma or ocular hypertension.
  • a pharmaceutical composition comprising a mixture of a compound as disclosed above and (i) a beta- adrenergic antagonist or (ii) a prostaglandin analog or (iii) an ⁇ -adrenergic agonist or a nitrooxy derivative thereof.
  • a pharmaceutical composition comprising a mixture of a compound as disclosed above and timolol or a nitrooxy derivative thereof.
  • a pharmaceutical composition comprising a mixture of a compound as disclosed above and latanoprost or a nitrooxy derivative thereof
  • a method for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies comprising administering a pharmaceutical composition as disclosed above Definitions
  • the term 'optionally substituted means that the specified group is unsubstituted or is substituted by one or more substituents
  • the terms “treat,” “treating” or “treatment” includes preventative
  • alkyl means a straight or branched chain saturated hydrocarbon Exemplary alkyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1 - methylbutyl, 2-methylbutyl, 3-methylbutyl, hexyl, isohexyl, heptyl, octyl and the like
  • alkenyl groups include but are not limited to vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and the like
  • alkynyl means a straight or branched chain hydrocarbon having at least one triple bond, i.e., a C ⁇ C.
  • alkynyl groups include but are not limited to acetylenyl, propargyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl and the like.
  • cycloalkyl means a cyclic saturated hydrocarbon.
  • cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
  • exemplary cycloalkenyl groups include but are not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and the like.
  • cycloalkynyl means a cyclic hydrocarbon having at least one triple bond, i.e., a C ⁇ C.
  • exemplary cycloalkynyl groups include but are not limited to cyclohexynyl, cycloheptynyl, cyclooctynyl and the like.
  • alkoxy means a straight or branched chain saturated alkyl group bonded through oxygen.
  • alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexoxy, isohexoxy, heptoxy, octoxy and the like.
  • alkylene means a straight chain or branched chain saturated hydrocarbon wherein a hydrogen atom is removed from each of the terminal carbons.
  • alkylene groups include but are not limited to methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene and the like.
  • cycloalkylaryl and "(CH 2 )t(C 3 -Ci 2 )cycloalkyl(C6- Cio)aryl” includes linear and/or fused ring systems such as 2,3-didydro-1 H-indene, 2- methyl-2,3-didydro-1 H-indene, 1 ,2,3,4-tetrahydronaphthalene, 2-methyl-1 , 2,3,4- tetrahydronaphthalene, 1-cyclopentylbenzene, 1-(2-methylcyclopentyl)benzene, 1-(3- methylcyclopentyl)benzene, 1-cyclohexylbenzene, 1-(2-methylcyclohexyl)benzene, 1-(3- methylcyclohexyl)benzene, 1-(4-methylcyclohexyl)benzene, and the like,
  • halo or halogen means fluoro, chloro, bromo or iodo.
  • aryl means an organic radical derived from an aromatic hydrocarbon by removal of hydrogen. Exemplary aryl groups include but are not limited to phenyl, biphenyl, naphthyl, and the like.
  • heterocyclic and “heterocyclyl” means an aromatic or non-aromatic cyclic group containing one to four heteroatoms each independently selected from O, S and N, wherein each group has from 3 to 10 atoms in its ring system
  • Non-aromatic heterocyclic groups include groups having only 3 atoms in their ring system, whereas aromatic heterocyclic groups have at least 5 atoms in their ring system
  • Heterocyclic groups include fused ring systems such as benzo-fused rings and the like
  • An exemplary 3 membered heterocyclic group is aziridine
  • 4 membered heterocyclic group is azetidinyl (derived from azetidine)
  • 5 membered heterocyclic group is thiazolyl
  • 7 membered ring heterocyclic group is azepinyl
  • a 10 membered heterocyclic group is quinolinyl
  • non-aromatic heterocyclic groups include but are not limited to pyrrolidinyl tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyr ⁇ d ⁇ nyl, 2-pyrrol ⁇ nyl, 3-pyrrol ⁇ nyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3-d ⁇ oxolany
  • a group derived from pyrrole may be pyrrol-1 -yl (N-attached) or pyrrol-3-yl (C-attached)
  • a group derived from imidazole may be ⁇ m ⁇ dazol-1 -yl (N-attached) or ⁇ m ⁇ dazol-3-yl (C-attached)
  • Heterocyclic groups may be optionally substituted on any ring carbon, sulfur or nitrogen atom(s) by one to two oxygens (oxo), per ring
  • An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo moieties is 1 , 1 -d ⁇ oxo-th ⁇ omorphol ⁇ nyl - 11
  • Exemplary five to six membered heterocyclic aromatic rings having one or two heteroatoms selected independently from oxygen, nitrogen and sulfur include but are not limited to isothiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl and the like.
  • Exemplary partially saturated, fully saturated or fully unsaturated five to eight membered heterocyclic rings having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen include but are not limited to 3H-1 ,2-oxathiolyl, 1 ,2,3- oxadizaolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl and the like.
  • FIG. 1 Further exemplary five membered rings are furyl, thienyl, 2H-pyrrolyl, 3H-pyrroyl, pyrrolyl, 2-pyrrolinyl, 3- pyrrolinyl, pyrrolidinyl, 1 ,3-dioxolanyl, oxazolyl, thiazolyl, thiazolyl, imidazolyl, 2H- imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolinyl, isoxazolyl, isothiazolyl, 1 ,2-dithiolyl, 1 ,3-dithiolyl, 3H-1 ,2-oxathiolyl, 1 ,2,3-oxadizaolyl, 1 ,2,4- oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadia
  • FIG. 1 For exemplary six member rings, 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1 ,2-dioxinyl, 1 ,3-dioxinyl, 1 ,4-dioxanyl, morpholinyl, 1 ,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1 ,3,5-thazinyl, 1 ,2,4-triazinyl, 1 ,2,3- trizainyl, 1 ,3,5-trithianyl, 4H-1 ,2-oxazinyl, 2H-1 ,3-oxazinyl, 6H-1 ,3-oxazinyl, 6H-1.2- oxazinyl, 1 ,4-oxazinyl, 2H-1 ,2-oxazinyl, 4H
  • Further exemplary seven membered rings are azepinyl, oxepinyl, thiepinyl and 1 ,2,4-diazepinyl. Further exemplary eight membered rings are cyclooctyl, cyclooctenyl and cyclooctadienyl.
  • Exemplary bicyclic rings are composed of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen are indolizinyl, indolyl, isoindolyl, 3H-indolyl, 1 H-isoindolyl, indolinyl, cyclopenta(b)pyridinyl, pyrano(3,4-b)pyrrolyl, benzofuryl, isobenzofuryl, benzo(b)thienyl, benzo(c)thienyl, 1 H-indazolyl, indoxazinyl, benzoxazolyl, anthranilyl, benzimidazolyi, benzthiazolyl, purinyl, 4Hquinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl,
  • Exemplary 3-10 membered heterocyclyl groups include but are not limited to oxetane azetidine, tetrahydrofuran, pyrrolidine, 2,5-d ⁇ hydro-1 H-pyrrole, 1 ,3-d ⁇ oxalane, isoxazolidine, oxazolidine, pyrazolidine, imidazolidine, pyrrol ⁇ d ⁇ n-2-one, tetrahydroth ⁇ ophene-1 ,1 -dioxide, pyrrol ⁇ d ⁇ ne-2,5-d ⁇ one, tetrahydro-2H-pyran, pipe ⁇ dine, 1 ,2,3,6-tetrahydropyr ⁇ d ⁇ ne, 1 ,4-d ⁇ oxane, morpholine, piperazine, thiomorpholine, p ⁇ per ⁇ d ⁇ n-2-one, p ⁇ per ⁇ d ⁇ n-4-one, th ⁇ omorphol ⁇ ne-1 ,1 -dioxide
  • a carbocyclic or heterocyclic moiety may be bonded or otherwise attached to a designated substrate, through differing ring atoms without denoting a specific point of attachment, then all possible points are intended, whether through a carbon atom or for example, a trivalent nitrogen atom
  • pyridyl means 2-, 3-, or 4-pyr ⁇ dyl
  • thienyl means 2-, or 3-th ⁇ enyl
  • Pharmaceutically acceptable salts of the compounds of the invention include the acid addition and base salts (including disalts) thereof
  • Suitable acid addition salts are formed from acids which form non-toxic salts
  • acids which form non-toxic salts
  • examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tart
  • Suitable base salts are formed from bases which form non-toxic salts Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts
  • bases which form non-toxic salts Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts
  • a pharmaceutically acceptable salt of a compound of the invention may be readily prepared by mixing together solutions of a compound of the invention and the desired acid or base as appropriate The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent The degree of ionization in the salt may vary from completely ionized to almost non-ionized
  • the compounds of the invention may exist in both unsolvated and solvated forms
  • 'solvate' is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol, water and the like
  • solvent molecules for example, ethanol, water and the like
  • 'hydrate' is included within the meaning of the term 'solvate" and is frequently used when the solvent is water
  • Pharmaceutically acceptable solvates in accordance with the invention include solvates (hydrates) wherein the solvent of crystallization may be isotopically substituted, e g D 2 O, de-acetone, d 6 -DMS0
  • the compounds of the invention which are complexes, such as clathrates and drug-host inclusion complexes are within the scope of the invention
  • the drug and host are present in stoichiometric or non- stoichiomet ⁇ c amounts
  • complexes containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts
  • the resulting complexes may be ionized, partially ionized, or non-ionized
  • the compounds of the invention include all compounds of the invention, polymorphs and isomers thereof, including optical, geometric and tautomeric isomers as hereinafter defined and isotopically-labeled compounds
  • the compounds of the invention containing one or more asymmetric carbon atoms may exist as two or more stereoisomers Where a compound contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautome ⁇ sm') can occur It follows that a single compound may exhibit more than one type of isomerism All stereoisomers, geometric isomers and tautomeric forms of the compounds of the invention are included within the scope of the invention, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof Also included are acid addition or base salts wherein the counterion is optically active, for example D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fraction
  • racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
  • chromatography typically HPLC
  • a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine.
  • the invention includes all pharmaceutically acceptable isotopically-labeled compounds of the invention, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 CI, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • Radioactive isotopes tritium, i.e., 3 H, and carbon-14, i.e., 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • substitution with positron emitting isotopes such as 11 C, 18 F, 15 O and 13 N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations.using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed
  • reaction-inert solvent and “inert solvent” refers to a solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product
  • the compounds of the invention may be prepared by processes known in the chemical arts, particularly in light of the description contained herein Certain processes for the manufacture of the compounds of the invention are provided as further features of the invention and are illustrated in the reaction schemes provided below and in the experimental section The use of various protecting groups in these reactions are also well known and are exemplified in Protective Groups In Organic Synthesis, Second Edition, T W Greene and P G M Wuts, John Wiley and Sons, lnc 1991 , pages 227-229, which is hereby incorporated by reference in its entirety for all purposes
  • the utility of the compounds of the invention as medical agents for the reduction of intraocular pressure and accordingly to treat glaucoma is demonstrated by the activity of the compounds in conventional assays, including the in vivo assay and a receptor binding assay Such assays also provide a means whereby the activities of the compounds can be compared to each other and with the activities of other known compounds The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases
  • the compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products They may be obtained, for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying Microwave or radio frequency drying may be used for this purpose
  • the compounds of the invention intended for pharmaceutical use may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof) Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients
  • excipient is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing
  • the compounds of the invention may be administered orally Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth
  • Formulations suitable for oral administration include solid formulations, such as tablets capsules containing particulates, liquids, or powders, lozenges (including liquid- filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive) ovules, sprays and liquid formulations
  • Liquid formulations include suspensions, solutions, syrups and elixirs Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet
  • the compounds of the invention may also be used in fast-dissolving, fast- disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 1 1 (6), 981-986 by Liang and Chen (2001 )
  • the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form
  • tablets generally contain a disintegrant
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate
  • the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form
  • Binders are generally used to impart cohesive qualities to a tablet formulation
  • Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc
  • surface active agents may comprise from 0 2 wt% to 5 wt% of the tablet, and glidants may comprise from 0 2 wt% to 1 wt% of the tablet
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate Lubricants generally comprise from 0 25 wt% to 10 wt%, preferably from 0 5 wt% to 3 wt% of the tablet
  • Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
  • the formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N. Y., 1980 (ISBN 0-8247-6918- X).
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001 ). The use of chewing gum to achieve controlled release is described in WO00/35298.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of 3 to 9), but, for some applications, they may be more suitably formulated as a sterile nonaqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of parenteral formulations under sterile conditions for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • the solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release
  • compounds of the invention may be formulated as a solid semi-solid or thixotropic liquid for administration as an implanted depot providing modified release of the active compound
  • examples of such formulations include drug- coated stents and PGLA [define] microspheres
  • the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermal ⁇
  • Typical formulations for this purpose include gels hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions Liposomes may also be used
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol Penetration enhancers may be incorporated [see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999) ]
  • compositions of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant such as 1 , 1 ,1 ,2-tetrafluoroethane or 1 ,1 , 1 ,2,3,3,3- heptafluoropropane
  • a suitable propellant such as 1 , 1 ,1 ,2-tetrafluoroethane or 1 ,1 , 1 ,2,3,3,3- heptafluoropropane
  • the pressurized container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate oleic acid, or an oligolactic acid P ⁇ or to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns)
  • This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying
  • Capsules made, for example, from gelatin or HPMC
  • blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter
  • Other suitable excipients include dextran glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose
  • a suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 ⁇ l to 100 ⁇ l
  • a typical formulation may comprise a compound of the invention, propylene glycol, sterile water, ethanol and sodium chloride
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol
  • Suitable flavors such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration
  • Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lact ⁇ c-coglycol ⁇ c acid (PGLA) Modified release formulations include delayed-, sustained-, pulsed-, controlled- , targeted and programmed release
  • PGLA poly(DL-lact ⁇ c-coglycol ⁇ c acid
  • the compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate
  • the compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH- adjusted, sterile saline
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (e g absorbable gel sponges, collagen) and nonbiodegradable (e g silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes
  • a polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride
  • Such formulations may also be delivered by iontophoresis
  • the compounds of the invention can be incorporated into various types of ophthalmic formulations for delivery to the eye These compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride and water to form an aqueous, sterile ophthalmic suspensions or solutions
  • a preservative in an appropriate vehicle such as, mineral oil, liquid lanolin, or white petrolatum
  • Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940 or the like according to the published formulations for analogous ophthalmic preparations, preservatives and tonicity agents can be incorporated
  • Ophthalmic solution formulations may be prepared by dissolving the active ingredient in a physiologically acceptable isotonic aqueous buffer Further, the ophthalmic solution may include an ophthalmologically
  • the compounds of the invention are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 5 to 7 8
  • the compounds will normally be contained in these formulations in an amount of 01 % to 10% by weight, but preferably in an amount of 0 25% to 5 0% by weight
  • 1 to 3 drops of these formulations would be delivered to the surface of the eye 1 to 4 times a day according to the routine discretion of a skilled clinician
  • the compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol- containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration
  • Drug-cyclodext ⁇ n complexes are found to be generally useful for most dosage forms and administration routes Both inclusion and non-inclusion complexes may be used As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i e as a carrier, diluent, or solubiliser Most commonly used for these purposes are alpha-, beta- and gamma-cyclodext ⁇ ns, examples of which may be found in International Patent Applications Nos WO 91 /1 1 172, WO 94/02518 and WO 98/55148 Dosage ranges are based on an average human subject having a weight of about
  • treatment may include one or more of curative, palliative and prophylactic treatment
  • the ability of the compounds of the invention to reduce intraocular pressure may be measured using the assay described below
  • Preferred compounds in accordance with the invention may be prepared in manners analogous to those specifically described below.
  • the examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations.
  • the skilled artisan will recognize that different acids, amines, alkyl halides, aryl halides, coupling reagents, and heterocycles may be substituted in the following descriptions to suit the preparations of a desired embodiment.
  • the following methods may be scaled upwards or downwards to suit the amount of desired material.
  • Step 1 3, 4-Difluorobenzenesulfonyl Chloride (a-2)
  • Step 6 4-[5-2, 4-Dimethylbenzyl-3-(hydroxymethyl)-1H-1 ,2,4-triazol-1-yl]-3- fluorobenzenesulfonamide (a-8)
  • the reaction was concentrated by rotary evaporation and the residue was partitioned between ethyl acetate and water.
  • the aqueous layer was adjusted to pH 1 with 1 M HCI.
  • the layers were separated and the ethyl acetate layer was washed with brine then dried with magnesium sulfate, filtered and concentrated by rotary evaporation.
  • the crude material was suspended in 30 ml_ of boiling ethanol and left standing overnight.
  • Step 8 4-[5-(2,5-dimethylbenzyl)-3-(iodomethyl)-1 W-1 ,2,4-triazoM -yl]-3- fluorobenzenesulfonamide (a-10)
  • Step 3 [1 -[4-(Aminosulfonyl)-2-f!uorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl (2-Chloroethoxy)acetate (c-4)
  • Step 4 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl (2-lodoethoxy)acetate (c-5)
  • Step 5 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]methyl [2-(Nitrooxy)ethoxy]acetate (C-1 )
  • Step 4 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]methyl [2-(2-lodoethoxy)ethoxy]acetate (d-5)
  • Step 5 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H- 1 ,2,4- t ⁇ azol-3-yl]methyl ⁇ 2-[2-(Nitrooxy)ethoxy]ethoxy ⁇ acetate (D-1)
  • Step 2 4-(1 tf-lmidazol-1 -ylcarbonyl)benzyl Nitrate (e-3)
  • Step 3 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 4-[(nitrooxy)methyl] Benzoate (E-1 )
  • Step 1 Methyl 2,2-Dimethyl-3-(nitrooxy)propanoate (f-2)
  • Step 4 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 2,2-Dimethyl-3-(nitrooxy)propanoate (F-1 )
  • Step 1 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl /V-(tert-butoxycarbonyl), L-Valinate (g-1 )
  • Step 2 [1 -[4-(Aminosulfonyl)-2-fIuorophenyl]-5-(2,5-dimethylbenzyl)-1 HA ,2,4- triazol-3-yl]methyl L-Valinate (g-2)
  • Step 3 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 HA ,2,4- tr ⁇ azol-3-yl]methyl ⁇ /-(4-bromobutanoyl), L-Valinate (g-3)
  • Step 4 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl ⁇ /-[4-(nitrooxy)butanoyl] L-Valinate (G-1 )
  • Step 1 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 4-nitrophenyl Carbonate (h-1 )
  • Step 2 [1 -[4-(Aminosu!fonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazo!-3-yl]methyl 2-(2-hydroxyethoxy)ethyl Carbonate (h-2)
  • Example E-1 Similar to the preparation of Example E-1 and method cited therein; a solution of diethylene glycol (0.296 mL, 3.10 mmol), scandium (III) triflate (122 mg, 0.248 mmol), and DMAP (253 mg, 2.07 mmol), in CH 2 CI 2 (1.5 mL), was cooled to 0 0 C and stirred for
  • Step 3 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1,2,4- triazol-3-yl]methyl 2-[2-(nitrooxy)ethoxy]ethyl Carbonate (H-1 )
  • Step 1 1 -tert-Butyl 2-Methyl (2S)-4-(Nitrooxy)pyrrolidine-1 ,2-dicarboxylate (j-2)
  • Step 2 1 -(ferf-Butoxycarbonyl)-4-(nitrooxy)-L-proline (j-3)
  • Step 4 tert-Butyl (2S)-2- ⁇ [( ⁇ 4-[3-( ⁇ [tert-Butyl(dimethyl)silyl]oxy ⁇ methyl)-5-(2,5- dimethylbenzyl)-1 H-1 ,2,4-triazol-1 -yl]-3-fluorophenyl ⁇ sulfonyl)amino]carbonyl ⁇ -4- (nitrooxy)pyrrolidine-i -carboxylate (j-5)
  • Step 5 ⁇ /-( ⁇ 4-[5-(2,5-Dimethylbenzyl)-3-(hydroxymethyl)-1 H-1 ,2,4-triazoM -yl]-3- fIuorophenyl ⁇ sulfonyl)-4-(nitrooxy)-L-prolinamide (J-1 )
  • Step 1 [1 - ⁇ 4-[(Acetylamin enyl ⁇ -5-(2,5-dimethylbenzyl)-1 H- 1 ,2,4-triazol-3-yl]methyl 4-(Ni )
  • Step 1 2- ⁇ [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl ⁇ 1 -te/t-Butyl (2S)-4-(nitrooxy)pyrrolidine-1 ,2-dicarboxylate (I-4)
  • Step 2 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 W-1 ,2,4- triazol-3-yl]methyl 4-(Nitrooxy)-L-prolinate (L-1 )
  • Step 2 (E.ZJ-N' ⁇ -IS ⁇ .S-DimethylbenzyO-S-formyl-I H-i ⁇ -triazol-i -yO-S- fluorophenylsulfonyl)-N,N-dimethylformamidine (m-2)
  • Step 3 4-(5-(2,5-Dimethylbenzyl)-3-(1 -hydroxyethyl)-1 H-1 ,2,4-triazol-1 -yl)-3- fluorobenzenesulfonamide (m-3)
  • the enantiomeric mixture T- 1 was resolved via preparative chiral SFC using a ChiralPak OJ-H, 20% MeOH @ 140 bar, 2.5 mL/min.
  • Step 4 1 -[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl [2-(2-chloroethoxy)ethoxy]acetate (m-4) Cl
  • Step 4 1 -[1 -[4-(Aminosulfonyl)-2-fIuorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl ⁇ 2-[2-(Nitrooxy)ethoxy]ethoxy ⁇ acetate (M-1)
  • the purified oil was then azeotroped with dichloromethane (2 x 10 ml_), dissolved in a minimal amount of deionized water, and lyophilized to dryness to provide the desired nitrate ester as a hygroscopic gum (0.23 g, 74%).
  • Step 1 4-(5-(2,5-Dimethylbenzyl)-3-formyl-1 H-1 ,2,4-triazoM -yl)-3- fluorobenzenesulfonamide (n-1 )
  • Step 2 4-(5-(2,5-D ⁇ methylbenzyl)-3-vinyl-1 H-1 ,2,4-triazol-1 -yl)-3- fluorobenzenesulfonamide (n-2)
  • Step 4 2-[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]-2-hydroxyethyl Nitrate (N-1 )
  • Step 1 tert-Butyl 3-(2- ⁇ 2-[2-(Nitrooxy)ethoxy]ethoxy ⁇ ethoxy)propanoate (o-2)
  • Step 3 ⁇ 1 -[4-(Am ⁇ nosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-124- tr ⁇ azol-3-yl ⁇ methyl 3-(2- ⁇ 2-[2-(N ⁇ trooxy)ethoxy]ethoxy ⁇ ethoxy)propanoate (0-1)
  • Step 1 12,12,13,13-Tetramethyl-3,6,11 -trioxa-12-silatetradec-1 -yl 4- Methylbenzenesulfonate (p-3)
  • Step 4 ⁇ 1-[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-124- triazol-3-yl ⁇ methyl 4- ⁇ 2-[2-(Nitrooxy)ethoxy]ethoxy ⁇ butanoate (P-1 )

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4 and RA through RE are as defined herein. The invention also relates to methods of treating glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy, retinal vasculopathies and intraocular pressure in mammals by administering the compounds of formula I, and to pharmaceutical compositions which contain the compounds of formula I for such treatments. The invention also relates to methods of preparing the compounds of formula (I).

Description

1- [4- (SULFONYL) -PHENYL] -5- (BENZYL) -IH-I, 2, 4-TRIAZOL DERIVATIVES AS INHIBITORS OF CARBONIC ANHYDRASE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION
Field of the Invention
The present invention relates to compounds of formula I:
Figure imgf000002_0001
(I) and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4 and
RA through RE are as defined herein. Methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for inhibiting carbonic anhydrase, and thereby lowering intraocular pressure and treating glaucoma are also provided.
Background of the Invention Glaucoma is optic nerve damage, often associated with increased intraocular pressure (lOP), that leads to progressive, irreversible loss of vision. Almost 3 million people in the United States and 14 million people worldwide have glaucoma; this is the third leading cause of blindness worldwide. Glaucoma occurs when an imbalance in production and drainage of fluid in the eye (aqueous humor) increases eye pressure to unhealthy levels.
It is known that elevated IOP can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-adrenergic antagonists, α-adrenergic agonists, cholinergic agents, prostaglandin analogs or carbonic anhydrase inhibitors.
Several side effects are associated with the drugs conventionally used to treat glaucoma. Topical beta-adrenergic antagonists show serious pulmonary side effects, depression, fatigue, confusion, impotence, hair loss, heart failure and bradycardia.
Topical α-adrenergic agonists have a fairly high incidence of allergic or toxic reactions; topical cholinergic agents (miotics) can cause visual side effects The topical prostaglandin analogs (bimatoprost, latanoprost, travoprost and unoprostone) used in the treatment of glaucoma can produce ocular side effects, such as increased pigmentation of the iris ocular irritation, conjunctival hyperaemia, iritis, uveitis and macular edema (Martindale, Thirty-third edition, p 1445)
Finally, the side effects associated with oral carbonic anhydrase inhibitors include fatigue, anorexia, depression, paresthesias and serum electrolyte abnormalities (The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, M H Beers and R Berkow Editors Sec 8, Ch 100) WO2006/052899 discloses novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions, for treating ophthalmic disorders comprising at least one nitrosated and/or nitrosylated compound, and optionally at least one nitric oxide donor and/or at least one therapeutic agent selected from the group consisting of an α-adrenergιc receptor agonist, an ACE inhibitor an antimicrobial a β-adrenergic antagonist, a carbonic anhydrase inhibitor, a non-steroidal anti-inflammatory drug, a prostaglandin, a COX-2 inhibitor and a steroid
Summary of the Invention
The present invention relates to new carbonic anhydrase inhibitor derivatives More particularly, the present invention relates to unique triazole-benzenesulfonamides, pharmaceutical compositions containing them, and their use as drugs for treating glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies
An object of the present invention to provide new derivatives of carbonic anhydrase inhibitors able not only to eliminate or at least reduce the side effects associated with the parent compounds, but also to improve pharmacological activity It has been surprisingly found that nitrooxydeπvatives of carbonic anhydrase inhibitors have a significantly improved overall profile as compared to native carbonic anhydrase inhibitors both in terms of wider pharmacological activity, enhanced tolerability and long- acting ocular hypotensive activity In particular, it has been recognized that the carbonic anhydrase inhibitor nitroderivatives of the present invention can be employed for treating ocular hypertension and preventing glaucoma Moreover, they have been found to be effective for the treatment of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies.
The compounds of the present invention are indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty.
An object of the present invention is a method for treating eye disorders, in particular glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor able to release nitric oxide.
A carbonic anhydrase inhibitor is a compound having an inhibition constant (Kj) against the isoenzyme CAM in the range of 0,01-200 nM. The carbonic anhydrase activity is measured according to the test on carbonic anhydrase inhibition as reported below. A carbonic anhydrase inhibitor able to release nitric oxide is a compound having an EC50 value in the range of 1-50μM, in vasorelaxation.
The compounds of the present invention are triazoles which inhibit carbonic anhydrase activity, and are thereby useful for lowering intraocular pressure and treating glaucoma, without producing significant systemic side effects when delivered topically to the eye.
In one aspect according to the invention, there is provided a compound of formula (I):
Figure imgf000004_0001
(I) - A -
o Il wherein R1 is H, (CrC10)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R . R 2 js (Crc6)alkyl or NR6R7; R3 is H or halo; each RA, RB, Rc, RD, and RE is independently H, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OR5, or -C(O)R5; each R5 is independently H, -OH, - NO2, -ONO2, (d-C6)alkyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, (C3-C10)cycloalkoxy, (C6- Cio)aryl, or (C6-Ci0)heteroaryl, wherein each of said (CrC6)alkyl, (C3-Ci0)cycloalkyl, (Cr C6)alkoxy, (C3-C10)cycloalkoxy, (C6-C10)aryl, and (C6-Ci0)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may o Il be the same or different, is independently H, -OH, -C(O)R8, or -C-R9 ; each R8 is independently (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (C4- Cio)heterocycloalkyl, (C6-C10)aryl, or (C6-Cio)heteroaryl, wherein each of said (C3- Cio)cycloalkyl, (C4-C10)heterocycloalkyl, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently - NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, [(d- C6)alkyl(O)]m, -C[0(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C1-C6)alkoxy(C1-C6)alkyl, (C3- Cio)cycloalkoxy, (Ci-C6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-C10)heterocycloalkyl, (C6-Cio)aryl, or (C6-Ci0)heteroaryl, wherein each of said (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (CrC6)alkoxy, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, - [O(CrC6)alkyl]mi (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(Ci-C6)alkoxy, (C4-Cio)heterocycloalkyl, (C6-C10)aryl, and (C6-Ci0)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(CrC10)alkoxy]NO2, [(CrC10)alkoxy]ONO2, [(CrC6)alkyl]ONO2, or [(d-C6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
In another aspect of the invention, there is provided a compound according to o formula (I) wherein R1 is -C(O)R5 or -C(O)C-R9 In a further aspect of the invention, there is provided a compound according to o M formula (I) wherein R1 is -COH, -C(O)NO2, -C(O)C-C[O(CrC6)alkyl]m-ONO2 _ -C(O)C-[(C1-C6)alkyl]m-ONO2 -C(O)C-[(C6-C10)aryl][(CrC6)alkyl]-ONO2
-C(O
Figure imgf000005_0001
In yet another aspect of the invention, there is provided a compound according to o Il formula (I) wherein R2 is NH2 or -NHC-R9
In another aspect of the invention, there is provided a compound according to
formula (I) wherein R2 is NH2 ,
Figure imgf000006_0001
N , or -N- C-CH3 In a further aspect of the invention, there is provided a compound according to formula (I) wherein R3 is selected from Br, Cl, F, and I.
In yet another aspect of the invention, there is provided a compound according to formula (I) wherein each RA, RB, Rc, RD, and RE is independently H or (CrC6)alkyl.
In another aspect of the invention, there is provided a compound according to formula (I) wherein RA and RD are (Ci-C6)alkyl, or RB and RE are (CrCeJalkyl.
In a further aspect of the invention, there is provided a compound according to formula (Ma):
Figure imgf000006_0002
(Ha) o Il wherein R1 is H, (CrC10)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R . R 2 js (CrC6)alkyl or NR6R7; each R5 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3- Cio)cycloalkyl, (d-C6)alkoxy, (C3-Ci0)CyClOaIkOXy, (C6-Ci0)aryl, or (C6-Ci0)heteroaryl, wherein each of said (CrC6)alkyl, (C3-C-ι0)cycloalkyl, (CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (C6-Cio)aryl, and (C6-Ci0)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may be the same or different, is o independently H, -OH, -C(O)R8, or -C-R ; each R8 is independently (Ci-C6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (C3-Cio)cycloalkyl, (C4-Ci0)heterocycloalkyl, (C6-C10)aryl, or (C6-Ci0)heteroaryl, wherein each of said (C3-Ci0)cycloalkyl, (C4-C10)heterocycloalkyl, (C6-Cio)aryl, and (C6-Ci0)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-Ci0)cycloalkyl, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[0(C1- C6)alkyl]m, (Ci-C6)alkoxy(Ci-C6)alkyl, (C3-C10)cycloalkoxy, (Ci-C6)alkyl(NH)nC(=O), - (NH)n(Ci-C6)alkoxy, (C4-C10)heterocycloalkyl, (C6-C10)aryl, or (C6-C10)heteroaryl, wherein each of said (d-CθJalkyl, (C2-Ce)alkenyl, (C2-Ce)alkynyl, (C3-Cio)cycloalkyl, (C1- C6)alkoxy, [(Ci-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-Ci0)aryl, and (C6-Cio)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, - ONO2, [(C1-C1COaIkOXy]NO2, [(CrC10)alkoxy]ONO2, [(CrC6)alkyl]ONθ2, or [(C1- C6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
In still another aspect according to the invention, there is provided a compound o Il according to formula (Ha) wherein R1 is -C(O)R5 or -C(°)c-R . In another aspect according to the invention, there is provided a compound o Il according to formula (Ha) wherein R1 is -COH, -C(O)NO2, -C(O)C-C[O(C1-C6)alkyl]m-ONO2
9 9
-C(O)C-[(CrC6)alkyl]m-ONO2 _ -C(O)C-[(C6-C10)aryl][(CrC6)alkyl]-ONO 2 _
O O
-C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 Qr -C(O)C-[O(CrC6)alkyl]m-ONO2
In yet a further aspect according to the invention, there is provided a compound o according to formula (Na) wherein R2 is NH2 or -NHC-R .
In still another aspect according to the invention, there is provided a compound o H " /\ o
— N— C ^ V-ONO2 H M according to formula (Na) wherein R2 is NH2 , N , or -N- C-CH3
In another aspect according to the invention, there is provided a compound according to formula (lib):
Figure imgf000008_0001
(iib)
O wherein: R1 is H, (CrC10)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R9 . R 2 is (Cr C6)alkyl or NR6R7; each R5 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3- C10)cycioalkyl, (CrC6)a!koxy, (C3-Ci0)cycloalkoxy, (C6-C-ιo)aryl, or (C6-Cio)heteroaryl, wherein each of said (d-C6)alkyl, (C3-C10)cycloalkyl, (CrC6)alkoxy, (C3-C10)cycloalkoxy, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may be the same or different, is o Il independently H, -OH, -C(O)R8, or ~C~R9 ; each R8 is independently (CrC6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (C3-Cio)cycloalkyl, (C4-Ci0)heterocycloalkyl, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (C3-Ci0)cycloalkyl, (C4-Cio)heterocycloalkyl, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-Ci0)cycloalkyl, [(C1-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[0(Cr C6)alkyl]m, (Ci-C6)alkoxy(CrC6)alkyl, (C3-C10)cycloalkoxy, (Ci-C6)alkyl(NH)nC(=O), - (NH)n(C-ι-C6)alkoxy, (C4-Cio)heterocycloalkyl, (C6-CiO)aryl, or (C6-Cio)heteroaryl, wherein each of said (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-Cio)cycloalkyl, (Cr C6)alkoxy, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-C10)heterocycloalkyl, (C6-C10)aryl, and (C6-C10)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, - ONO2, [(CrC10)alkoxy]Nθ2, [(CrC10)alkoxy]ONO2, [(Ci-C6)alkyl]ONO2, or [(Cr C6)alkyl]Nθ2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
In yet another aspect according to the invention, there is provided a compound o Il according to formula (lib) wherein R1 is -C(O)R5 or -C(°)C-R9 . In still another aspect according to the invention, there is provided a compound o
Il according to formula (lib) wherein R1 is -COH, -C(O)NO2, -c(O)C-C[O(CrC6)alkyl]m-ONO2 _ o o
-C(O)C-[(CrC6)alkyl]m-ONO2 -C(O)C-[(C6-C10)aryl][(C1-C6)alkyl]-ONO2 o o
-C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 _ Qr -C(O)C-[O(CrC6)alkyl]m-ONO2
In a further aspect according to the invention, there is provided a compound o Il according to formula (lib) wherein R2 is NH2 or -NHC-R9
In yet another aspect according to the invention, there is provided a compound
according to formula (lib) wherein R2 is NH2 ,
Figure imgf000009_0001
N , or N c CH3 .
In another aspect according to the invention, there is provided a compound according to formula (Ilia):
Figure imgf000009_0002
(Ilia) o wherein: R10 is H or C"R13 ; R11 is H, (CrC10)alkyl, -OR12, -C(O)R12, -C(O)OR12, or o -C(O)C-R13 . each R i2 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3- Cio)cycloalkyl, (CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (C6-Ci0)aryl, or (C6-Ci0)heteroaryl, wherein each of said (CrC6)alkyl, (C3-Cio)cycloalkyl, (Ci-C6)alkoxy, (C3-Cio)cycloalkoxy, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R12 groups is optionally substituted by one or more R13 moieties; R13 is independently -NO2, -ONO2, (CrC6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, [(Ci-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, - [O(Ci-C6)alkyl]m, (Ci-C6)alkoxy(Ci-C6)alkyl, (C3-C10)cycloalkoxy, (C1-
C6)a!kyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-C10)heterocycloalkyl, (C6-Ci0)aryl, or (C6- Cio)heteroaryl, wherein each of said (d-CβJalkyl, (C2-Ce)alkenyl, (C2-C6)alkynyl, (C3- C10)cycloalkyl, (C1-C6JaIkOXy1 [(C1-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (Cs-Ciojcycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-
Cio)heterocycloalkyl, (C6-CiO)aryl, and (C6-C-io)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(Ci-Ci0)alkoxy]NO2, [(C1-C10)alkoxy]ONO2, [(C1- Ce)alkyl]ONθ2, or [(CrC6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof. In still another aspect according to the invention, there is provided a compound o Il according to formula (Ilia) wherein R10 is H or -C-R13 .
In a further aspect according to the invention, there is provided a compound
-ONO, 9 according to formula (Ilia) wherein R10 is H, N , or c CH3 .
In yet another aspect according to the invention, there is provided a compound o according to formula (Ilia) wherein R11 is -C(O)R12 or -C(O)C-R13
In another aspect according to the invention, there is provided a compound o Il according to formula (Ilia) wherein R11 is -COH, -C(O)NO2, -C(O)C-C[O(CrC6)alkyl]m-ONO2
-C(O)C-[(CrC6)alkyl]m-ONO2 -C(O)C-[(C6-C10)aryl][(Cl-C6)alkyl]-ONO2
-C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 _ Q{. -C(O)C-[O(C1-C6)alkyl]m-ONO2 In still a further aspect according to the invention, there is provided a compound according to a compound of formula (NIb):
Figure imgf000011_0001
(IMb) o Il wherein: R10 is H or C"R13 ; R11 is H, (CrC10)alkyl, -OR12, -C(O)R12, -C(O)OR12, or
O
Il
-C(O)C-R13 . each R i2 is jndependently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3- C10)cycloalkyl, (CrC6)alkoxy, (C3-C10)cycloalkoxy, (C6-C10)aryl, or (C6-Ci0)heteroaryl, wherein each of said (Ci-C6)alkyl, (C3-Cio)cycloalkyl, (CrC6)alkoxy, (C3-Cio)cycloalkoxy, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R12 groups is optionally substituted by one or more R13 moieties; R13 is independently -NO2, -ONO2, (C-ι-C6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, - [O(CrC6)alkyl]m, (Ci-C6)alkoxy(CrC6)alkyl, (C3-Ci0)CyClOaIkOXy, (d-
C6)alkyl(NH)nC(=O), -(NH)n(Ci-C6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-C10)aryl, or (C6- Cio)heteroaryl, wherein each of said (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- Cio)cycloalkyl, (CrC6)alkoxy, [(Ci-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(C1-C6)alkyl]m, (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4- Cio)heterocycloalkyl, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(CrC10)alkoxy]NO2, [(CrCio)alkoxy]ON02, [(d- C6)alkyl]ONO2, or [(CrCe)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
In another aspect according to the invention, there is provided a compound o Il according to formula (lllb) wherein R10 is H or ~C~R .
In still another aspect according to the invention, there is provided a compound
according to formula (lllb) wherein R10 is H,
Figure imgf000011_0002
CH3 In yet another aspect according to the invention, there is provided a compound o according to formula (INb) wherein R11 is -C(O)R12 or "C(°)C-R13 .
In a further aspect according to the invention, there is provided a compound o Il according to formula (NIb) wherein R11 is -COH, -C(O)NO2, -c(°)C-C[O(CrC6)alkyl]m-ONO2 o
Il O
-C(O)C-[(CrC6)alkyl]m-ONO2 -C(O)C-[(Cβ-C10)aryl][(C1-C6)alkyl]-ONO2
O O
-C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 _ Q|. -C(O)C-]O(CrC6)alkyl]m-ONO2
In another aspect according to the invention, there is provided a compound selected from the group consisting of:
Figure imgf000012_0001
Chiral
Figure imgf000014_0001
or a pharmaceutically acceptable salt or solvate thereof.
In still a further aspect according to the invention, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of one or more compounds according to the above disclosure.
In another aspect according to the invention, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to the above disclosure in a suitable form for topical administration.
In yet another aspect according to the invention, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a. compound according to the above disclosure for the treatment of glaucoma and ocular hypertension.
In still another aspect according to the invention, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to the above disclosure, wherein the compound of formula I is administered as a solution, suspension or emulsion in an ophthalmically acceptable vehicle.
In a further aspect according to the invention, there is provided a method for treating glaucoma or ocular hypertension, wherein the method comprises contacting an effective intraocular pressure reducing amount of a pharmaceutical composition according to the above disclosure with the eye in order to reduce eye pressure and to maintain the pressure at a reduced level.
In another aspect according to the invention, there is provided a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide and/or where the eye disorder is selected from glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies. In yet another aspect according to the invention, there is provided a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide wherein the carbonic anhydrase inhibitor is a compound having an inhibition constant (Kj) against the isoenzyme CAII in the range of 0.01 to 200 nM.
In still yet another aspect according to the invention, there is provided a method for treating eye disorders in a patient in need thereof comprising administering a therapeutically effective amount of a carbonic anhydrase inhibitor according to the above disclosure able to release nitric oxide wherein the carbonic anhydrase inhibitor able to release nitric oxide is a compound having an EC50 value in the range of 1 to 50 μM.
In a further aspect according to the invention, there is provided a method for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies comprising administering one or more compounds or pharmaceutical compositions according to the above disclosure.
In yet another aspect of the invention, there is provided one or more compounds as disclosed above for use as a medicament, or for the preparation of a medicament for treating glaucoma or ocular hypertension. In a further aspect of the invention, there is provided a pharmaceutical composition comprising a mixture of a compound as disclosed above and (i) a beta- adrenergic antagonist or (ii) a prostaglandin analog or (iii) an α-adrenergic agonist or a nitrooxy derivative thereof.
In another aspect of the invention, there is provided a pharmaceutical composition comprising a mixture of a compound as disclosed above and timolol or a nitrooxy derivative thereof. In still another aspect of the invention, there is provided a pharmaceutical composition comprising a mixture of a compound as disclosed above and latanoprost or a nitrooxy derivative thereof
In yet another aspect of the invention, there is provided a pharmaceutical kit for simultaneous, successive or previous administration of a pharmaceutical composition as disclosed above and (i) a beta-adrenergic antagonists or (ii) a prostaglandin analog or (MI) an α-adrenergιc agonist or a nitrooxy derivative thereof
In a further aspect of the invention, there is provided a method for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies comprising administering a pharmaceutical composition as disclosed above Definitions
As used herein, the terms "comprising" and "including" are used in their open, non-limiting sense As used herein, the term "substituted," means that the specified group or moiety bears one or more substituents The term "unsubstituted," means that the specified group bears no substituents
As used herein, the term 'optionally substituted" means that the specified group is unsubstituted or is substituted by one or more substituents As used herein, the terms "treat," "treating" or "treatment" includes preventative
(e g , prophylactic) and palliative treatment
As used herein, the term "pharmaceutically acceptable" means the carrier, diluent, excipients and/or salt must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof As used herein, the term "alkyl" means a straight or branched chain saturated hydrocarbon Exemplary alkyl groups include but are not limited to methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1 - methylbutyl, 2-methylbutyl, 3-methylbutyl, hexyl, isohexyl, heptyl, octyl and the like
As used herein, the term "alkenyl" means a straight or branched chain hydrocarbon having at least one double bond, i e a C=C Exemplary alkenyl groups include but are not limited to vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and the like As used herein, the term "alkynyl" means a straight or branched chain hydrocarbon having at least one triple bond, i.e., a CΞC. Exemplary alkynyl groups include but are not limited to acetylenyl, propargyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl and the like. As used herein, the term "cycloalkyl" means a cyclic saturated hydrocarbon.
Exemplary cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
As used herein, the term "cycloalkenyl" means a cyclic hydrocarbon having at least one double bond, i.e., a C=C. Exemplary cycloalkenyl groups include but are not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and the like.
As used herein, the term "cycloalkynyl" means a cyclic hydrocarbon having at least one triple bond, i.e., a CΞC. Exemplary cycloalkynyl groups include but are not limited to cyclohexynyl, cycloheptynyl, cyclooctynyl and the like. As used herein, the term "alkoxy" means a straight or branched chain saturated alkyl group bonded through oxygen. Exemplary alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy, tert-pentoxy, hexoxy, isohexoxy, heptoxy, octoxy and the like.
As used herein, the term "alkylene" means a straight chain or branched chain saturated hydrocarbon wherein a hydrogen atom is removed from each of the terminal carbons. Exemplary alkylene groups include but are not limited to methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene and the like.
As used herein, the term "cycloalkylaryl" and "(CH2)t(C3-Ci2)cycloalkyl(C6- Cio)aryl" includes linear and/or fused ring systems such as 2,3-didydro-1 H-indene, 2- methyl-2,3-didydro-1 H-indene, 1 ,2,3,4-tetrahydronaphthalene, 2-methyl-1 , 2,3,4- tetrahydronaphthalene, 1-cyclopentylbenzene, 1-(2-methylcyclopentyl)benzene, 1-(3- methylcyclopentyl)benzene, 1-cyclohexylbenzene, 1-(2-methylcyclohexyl)benzene, 1-(3- methylcyclohexyl)benzene, 1-(4-methylcyclohexyl)benzene, and the like,
As used herein, the term "halo" or "halogen" means fluoro, chloro, bromo or iodo. As used herein, the term "aryl" means an organic radical derived from an aromatic hydrocarbon by removal of hydrogen. Exemplary aryl groups include but are not limited to phenyl, biphenyl, naphthyl, and the like. As used herein, the terms "heterocyclic" and "heterocyclyl" means an aromatic or non-aromatic cyclic group containing one to four heteroatoms each independently selected from O, S and N, wherein each group has from 3 to 10 atoms in its ring system Non-aromatic heterocyclic groups include groups having only 3 atoms in their ring system, whereas aromatic heterocyclic groups have at least 5 atoms in their ring system Heterocyclic groups include fused ring systems such as benzo-fused rings and the like An exemplary 3 membered heterocyclic group is aziridine, 4 membered heterocyclic group is azetidinyl (derived from azetidine), 5 membered heterocyclic group is thiazolyl, 7 membered ring heterocyclic group is azepinyl, and a 10 membered heterocyclic group is quinolinyl
Examples of non-aromatic heterocyclic groups include but are not limited to pyrrolidinyl tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyrιdιnyl, 2-pyrrolιnyl, 3-pyrrolιnyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3-dιoxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabιcyclo[3 1 0]hexanyl, 3-azabιcyclo[4 1 O]heptanyl, 3H-ιndolyl and quinolizinyl Examples of aromatic heterocyclic (heteroaryl) groups include but are not limited to pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, tπazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl naphthyridinyl, and furopyridinyl
The foregoing groups may be C-attached or N-attached where such is possible For instance, a group derived from pyrrole may be pyrrol-1 -yl (N-attached) or pyrrol-3-yl (C-attached) Further, a group derived from imidazole may be ιmιdazol-1 -yl (N-attached) or ιmιdazol-3-yl (C-attached) Heterocyclic groups may be optionally substituted on any ring carbon, sulfur or nitrogen atom(s) by one to two oxygens (oxo), per ring An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo moieties is 1 , 1 -dιoxo-thιomorpholιnyl - 11
Exemplary five to six membered heterocyclic aromatic rings having one or two heteroatoms selected independently from oxygen, nitrogen and sulfur include but are not limited to isothiazolyl, pyridinyl, pyridiazinyl, pyrimidinyl, pyrazinyl and the like.
Exemplary partially saturated, fully saturated or fully unsaturated five to eight membered heterocyclic rings having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen include but are not limited to 3H-1 ,2-oxathiolyl, 1 ,2,3- oxadizaolyl, 1 ,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl and the like. Further exemplary five membered rings are furyl, thienyl, 2H-pyrrolyl, 3H-pyrroyl, pyrrolyl, 2-pyrrolinyl, 3- pyrrolinyl, pyrrolidinyl, 1 ,3-dioxolanyl, oxazolyl, thiazolyl, thiazolyl, imidazolyl, 2H- imidazolyl, 2-imidazolinyl, imidazolidinyl, pyrazolyl, 2-pyrazolinyl, pyrazolinyl, isoxazolyl, isothiazolyl, 1 ,2-dithiolyl, 1 ,3-dithiolyl, 3H-1 ,2-oxathiolyl, 1 ,2,3-oxadizaolyl, 1 ,2,4- oxadiazolyl, 1 ,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3-triazolyl, 1 ,2,4-trizaolyl, 1 ,3,4- thiadiazolyl, 1 ,2,3,4-oxatriazolyl, 1 ,2,3,5-oxatrizaolyl, 3H-1 ,2,3-dioxazolyl, 1 ,2,4- dioxazolyl, 1 ,3,2-dioxazolyl, 1 ,3,4-dioxazolyl, 5H-1 ,2,5-oxathiazolyl and 1 ,3-oxathiolyl. Further exemplary six member rings are 2H-pyranyl, 4H-pyranyl, pyridinyl, piperidinyl, 1 ,2-dioxinyl, 1 ,3-dioxinyl, 1 ,4-dioxanyl, morpholinyl, 1 ,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1 ,3,5-thazinyl, 1 ,2,4-triazinyl, 1 ,2,3- trizainyl, 1 ,3,5-trithianyl, 4H-1 ,2-oxazinyl, 2H-1 ,3-oxazinyl, 6H-1 ,3-oxazinyl, 6H-1.2- oxazinyl, 1 ,4-oxazinyl, 2H-1 ,2-oxazinyl, 4H-1 ,4-oxazinyi, 1 ,2,5-oxathiazinyl, 1 ,4-oxazinyl, o-isoxazinyl, p-isoxazinyl, 1 ,2,5-oxathiazinyl, 1 ,2,6-oxathiazinyl, 1 ,4,2-oxadiazinyl and 1 ,3,5,2-oxadiazinyl. Further exemplary seven membered rings are azepinyl, oxepinyl, thiepinyl and 1 ,2,4-diazepinyl. Further exemplary eight membered rings are cyclooctyl, cyclooctenyl and cyclooctadienyl.
Exemplary bicyclic rings are composed of two fused partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen are indolizinyl, indolyl, isoindolyl, 3H-indolyl, 1 H-isoindolyl, indolinyl, cyclopenta(b)pyridinyl, pyrano(3,4-b)pyrrolyl, benzofuryl, isobenzofuryl, benzo(b)thienyl, benzo(c)thienyl, 1 H-indazolyl, indoxazinyl, benzoxazolyl, anthranilyl, benzimidazolyi, benzthiazolyl, purinyl, 4Hquinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1 ,8-naphthyridinyl, pteridinyl, indenyl, isoindenyl, naphthyl, tetralinyl, decalinyl, 2H-1-benzopyranyl, pyrido(3,4-b)-pyridinyl, pyrido(3,2-b)-pyhdinyl, pyπdo(4,3-b)-pyrιdιnyl, 2H-1 ,3-benzoxazιnyl, 2H-1 ,4-benzoxazιnyl, 1 H-2,3-benzoxazιnyl, 4H-3 1 -benzoxazιnyl, 2H-1 2-benzoxazιnyl and 4H-1 ,4-benzoxazιnyl
Exemplary 3-10 membered heterocyclyl groups include but are not limited to oxetane azetidine, tetrahydrofuran, pyrrolidine, 2,5-dιhydro-1 H-pyrrole, 1 ,3-dιoxalane, isoxazolidine, oxazolidine, pyrazolidine, imidazolidine, pyrrolιdιn-2-one, tetrahydrothιophene-1 ,1 -dioxide, pyrrolιdιne-2,5-dιone, tetrahydro-2H-pyran, pipeπdine, 1 ,2,3,6-tetrahydropyrιdιne, 1 ,4-dιoxane, morpholine, piperazine, thiomorpholine, pιperιdιn-2-one, pιperιdιn-4-one, thιomorpholιne-1 ,1 -dioxide, 1 ,3-oxazιnan-2-one, morpholιn-3-one, pιperazιne-2-one, azepane, 1 ,4-oxazepane, 1 ,4-dιazepane, azepan-2- one, 1 ,4-dιazepan-5-one, quinuclidine, 2-aza-bιcyclo[2 2 1]heptane, 8-aza- bicyclo[3 2 1]octane, 5-oxa-2-aza-bιcyclo[2 2 1]heptane, 2-oxa-5-aza- bιcyclo[2 2 1]heptan-3-one, 2-oxa-5-aza-bιcyclo[2 2 2]octan-3-one, 1-methyl-5,6- pyrrolyl-7-oxa-bιcyclo[2 2 1]heptane, 6-aza-bιcyclo[3 2 1]octane, 3,8-dιaza- bιcyclo[3 2 1]octan-2-one, 2,2-dιmethyl-tetrahydro-3aH-[1 ,3]dιoxolo[4,5-c]pyrrole, 3,3- cyclohexylpyrrolidine, 1 ,5-dιaxo-9-azaspιro[5 5]undecane, octahydro-1 H-ιsoιndole, decahydroquinoline decahydroisoquinoline octahydropyrrolo[1 ,2a]pyrazιne, octahydro 1 H-pyrιdo[1 2a]pyrazιne, octahydropyrrolo[3,4-c]pyrιdιne-3-one, decahydropyrazιno[1 ,2-a]azepιne, furan, 1 H-pyrrole, isoxazole, oxazole, 1 H-pyrazole, I H-imidazole, thiazole, 1 ,2,4-oxadιazole, 1 ,3,4-oxadιazole, 4H-1 ,2,4-trιazole, 1 H- tetrazole, pyridine, pyπdazine, pyπmidine, pyrazine, pyrιdιne-2(1 H)-one, 1 ,4,5,6- tetrahydrocyclopenta[c]pyrazole, 6,7-dιhydro-5H-pyrrolo[2,1-c][1 ,2,4]trιazole, 2,3- dιhydroιmιdazo[2,1 -b]thιazole, ιmιdazo[2,1-b][1 ,3,4-c]pyrιdιne, 4,5,6,7-tetrahydro-3H- ιmιdazo[4,5-c]pyπdιne, 5,6,7,8-tetrahydroιmιdazo[1 ,5-a]pyrazιne, 4,5,6,7- tetrahydrothιazole[5,4-c]pyrιdιne, 5,6,7,8-tetrahydro-[1 ,2,4]trιazolo[4,3-a]pyrazine, quinoline, isoquinoline, 2,3-dιhydrobenzofuran, 5,6,7,8-tetrahydroquιnolιne, 3,4-dιhydro- 1 H-ιsochromene, 1 ,2,3,4-tetrahydroιsoquιnolιne, 4H-benzo[d][1 ,3]dιoxane, 5,6,7,8- tetrahydropyπdo[3,4-d]pyπmιdιne, benzofuran, 1 H-ιndole, benzo[d]oxazole, 1 H- benzo[d]ιmιdazole, H-ιmιdazo[1 ,2-a]pyπdιne, ιmιdazo[1 ,2-a]pyπmιdιne, 5,6,7,8- tetrahydroιmιdazo[1 5-a]pyrazιne-3(2H)-one, 2,3,4,5-tetrahydro-1 H-benzo[d]azepιne, 2 3 4 5-tetrahydrobenzo[f][1 ,4]oxazepιne, 5,6,7,8-tetrahydro-4H-ιsoxazolo[4,3-d]azepιne and6 7 8,9-tetrahydro-2H-[1 ,2,4]trιazolo[4,3-g][1 ,4]dιazepιn-3(5H)-one
It is to be understood that if a carbocyclic or heterocyclic moiety may be bonded or otherwise attached to a designated substrate, through differing ring atoms without denoting a specific point of attachment, then all possible points are intended, whether through a carbon atom or for example, a trivalent nitrogen atom For example, the term "pyridyl" means 2-, 3-, or 4-pyrιdyl, the term "thienyl" means 2-, or 3-thιenyl, and so forth Pharmaceutically acceptable salts of the compounds of the invention include the acid addition and base salts (including disalts) thereof
Suitable acid addition salts are formed from acids which form non-toxic salts Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts
Suitable base salts are formed from bases which form non-toxic salts Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts For a review on suitable salts, see "Handbook of Pharmaceutical Salts Properties Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002)
A pharmaceutically acceptable salt of a compound of the invention may be readily prepared by mixing together solutions of a compound of the invention and the desired acid or base as appropriate The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent The degree of ionization in the salt may vary from completely ionized to almost non-ionized
The compounds of the invention may exist in both unsolvated and solvated forms The term 'solvate' is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol, water and the like The term 'hydrate' is included within the meaning of the term 'solvate" and is frequently used when the solvent is water Pharmaceutically acceptable solvates in accordance with the invention include solvates (hydrates) wherein the solvent of crystallization may be isotopically substituted, e g D2O, de-acetone, d6-DMS0
The compounds of the invention which are complexes, such as clathrates and drug-host inclusion complexes are within the scope of the invention In contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non- stoichiometπc amounts Also included are complexes containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts The resulting complexes may be ionized, partially ionized, or non-ionized For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Halebhan (August 1975)
The compounds of the invention include all compounds of the invention, polymorphs and isomers thereof, including optical, geometric and tautomeric isomers as hereinafter defined and isotopically-labeled compounds
The compounds of the invention containing one or more asymmetric carbon atoms may exist as two or more stereoisomers Where a compound contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomeπsm') can occur It follows that a single compound may exhibit more than one type of isomerism All stereoisomers, geometric isomers and tautomeric forms of the compounds of the invention are included within the scope of the invention, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof Also included are acid addition or base salts wherein the counterion is optically active, for example D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC)
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of the invention contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture.
Mixtures of stereoisomers may be separated by conventional techniques known to those skilled in the art [see, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel (Wiley, New York, 1994)].
The invention includes all pharmaceutically acceptable isotopically-labeled compounds of the invention, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36CI, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulphur, such as 35S.
Certain isotopically-labelled compounds of the invention, for example those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e., 3H, and carbon-14, i.e., 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy
Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations.using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed
As used herein, the expressions "reaction-inert solvent" and "inert solvent" refers to a solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product
The parenthetical negative or positive sign used herein in the nomenclature denotes the direction plane polarized light is rotated by the particular stereoisomer
One of ordinary skill will recognize that certain compounds of the invention may contain one or more atoms which may be in a particular stereochemical or geometric configuration, giving rise to stereoisomers and configurational isomers All such isomers and mixtures thereof are included in the invention Solvates (hydrates) of the compounds of the invention are also included
Other features and advantages will be apparent from the specification and claims which describe the invention Detailed Description of the Invention
In general, the compounds of the invention may be prepared by processes known in the chemical arts, particularly in light of the description contained herein Certain processes for the manufacture of the compounds of the invention are provided as further features of the invention and are illustrated in the reaction schemes provided below and in the experimental section The use of various protecting groups in these reactions are also well known and are exemplified in Protective Groups In Organic Synthesis, Second Edition, T W Greene and P G M Wuts, John Wiley and Sons, lnc 1991 , pages 227-229, which is hereby incorporated by reference in its entirety for all purposes The utility of the compounds of the invention as medical agents for the reduction of intraocular pressure and accordingly to treat glaucoma is demonstrated by the activity of the compounds in conventional assays, including the in vivo assay and a receptor binding assay Such assays also provide a means whereby the activities of the compounds can be compared to each other and with the activities of other known compounds The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases
The compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products They may be obtained, for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying Microwave or radio frequency drying may be used for this purpose
The compounds of the invention intended for pharmaceutical use may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof) Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form
Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing
Company, 1995) ]
The compounds of the invention may be administered orally Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth
Formulations suitable for oral administration include solid formulations, such as tablets capsules containing particulates, liquids, or powders, lozenges (including liquid- filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive) ovules, sprays and liquid formulations
Liquid formulations include suspensions, solutions, syrups and elixirs Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet
The compounds of the invention may also be used in fast-dissolving, fast- disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 1 1 (6), 981-986 by Liang and Chen (2001 )
For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form In addition to the drug, tablets generally contain a disintegrant Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form
Binders are generally used to impart cohesive qualities to a tablet formulation Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate
Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc When present, surface active agents may comprise from 0 2 wt% to 5 wt% of the tablet, and glidants may comprise from 0 2 wt% to 1 wt% of the tablet
Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate Lubricants generally comprise from 0 25 wt% to 10 wt%, preferably from 0 5 wt% to 3 wt% of the tablet
Other possible ingredients include anti-oxidants colourants, flavouring agents, preservatives and taste-masking agents Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N. Y., 1980 (ISBN 0-8247-6918- X).
The foregoing formulations for the various types of administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001 ). The use of chewing gum to achieve controlled release is described in WO00/35298.
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques. Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of 3 to 9), but, for some applications, they may be more suitably formulated as a sterile nonaqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water. The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents
Formulations for parenteral administration may be formulated to be immediate and/or modified release Thus, compounds of the invention may be formulated as a solid semi-solid or thixotropic liquid for administration as an implanted depot providing modified release of the active compound Examples of such formulations include drug- coated stents and PGLA [define] microspheres
The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermal^ Typical formulations for this purpose include gels hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions Liposomes may also be used Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol Penetration enhancers may be incorporated [see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999) ]
Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e g Powderject™ , Bioject™, etc ) injection The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant such as 1 , 1 ,1 ,2-tetrafluoroethane or 1 ,1 , 1 ,2,3,3,3- heptafluoropropane For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin
The pressurized container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate oleic acid, or an oligolactic acid Pπor to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns)
This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate The lactose may be anhydrous or in the form of the monohydrate, preferably the latter Other suitable excipients include dextran glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose
A suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1 μg to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 μl to 100 μl A typical formulation may comprise a compound of the invention, propylene glycol, sterile water, ethanol and sodium chloride Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol
Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration
Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactιc-coglycolιc acid (PGLA) Modified release formulations include delayed-, sustained-, pulsed-, controlled- , targeted and programmed release
The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate
The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH- adjusted, sterile saline Other formulations suitable for ocular and aural administration include ointments, biodegradable (e g absorbable gel sponges, collagen) and nonbiodegradable (e g silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride Such formulations may also be delivered by iontophoresis
The compounds of the invention can be incorporated into various types of ophthalmic formulations for delivery to the eye These compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride and water to form an aqueous, sterile ophthalmic suspensions or solutions In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle such as, mineral oil, liquid lanolin, or white petrolatum Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940 or the like according to the published formulations for analogous ophthalmic preparations, preservatives and tonicity agents can be incorporated Ophthalmic solution formulations may be prepared by dissolving the active ingredient in a physiologically acceptable isotonic aqueous buffer Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the active ingredient Furthermore, the ophthalmic solution may contain a thickener such as hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methyl-cellulose, polyvinylpyrrolidone, or the like to improve the retention of the medicament in the conjunctival sac
The compounds of the invention are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 5 to 7 8 The compounds will normally be contained in these formulations in an amount of 01 % to 10% by weight, but preferably in an amount of 0 25% to 5 0% by weight Thus, for topical presentation 1 to 3 drops of these formulations would be delivered to the surface of the eye 1 to 4 times a day according to the routine discretion of a skilled clinician The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol- containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration
Drug-cyclodextπn complexes, for example, are found to be generally useful for most dosage forms and administration routes Both inclusion and non-inclusion complexes may be used As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i e as a carrier, diluent, or solubiliser Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextπns, examples of which may be found in International Patent Applications Nos WO 91 /1 1 172, WO 94/02518 and WO 98/55148 Dosage ranges are based on an average human subject having a weight of about
65 kg to 70 kg The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly Depending on the disease and condition of the patient, the term "treatment" as used herein may include one or more of curative, palliative and prophylactic treatment The ability of the compounds of the invention to reduce intraocular pressure may be measured using the assay described below
The following non-limiting preparations and Examples illustrate the preparation of the compounds of the invention Examples In the examples described below, unless otherwise indicated, all temperatures are set forth in degrees Celsius and all parts and percentages are by weight Reagents may be purchased from commercial suppliers, such as Sigma-Aldπch Chemical Company, Acros Organics, or Lancaster Synthesis Ltd and may be used without further purification unless otherwise indicated Tetrahydrofuran (THF), methylene chloride (CH2CI2 or DCM), N, N-dimethylacetamide (DMA), acetonitπle (MeCN), and N1N- dimethylformamide (DMF) may be purchased from Aldrich in Sure-Seal bottles and used as received All solvents may be purified using standard methods known to those skilled in the art, unless otherwise indicated Diethyl ether is abbreviated as Et2O Ethyl acetate is abbreviated as EtOAc Trifluoroacetic acid is abbreviated as TFA Acetic acid is abbreviated as HOAc or AcOH Similarly, acetyl chloride is abbreviated as AcCI Coupling reagent 0-(7-azabenzotrιazol-1 -yl)-Λ/,/\/,Λ/',Λ/'-tetra-methyluronιum hexafluorophosphate is abbreviated as HATU Trifluoromethanesulfonate, or triflate, is abbreviated as "OTf " t-Butyldimethylsilyl is abbreviated as TBS terf-Butoxycarbonyl is abbreviated as BOC N,N-Dι-ιsopropyl-N-ethylamιne is abbreviated as /-Pr2NEt 4-(N, N- Dιmethylamιno)pyrιdιne is abbreviated as DMAP
The reactions set forth below were done generally under a positive pressure of argon or nitrogen or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe Glassware was oven dried and/or heat dried Analytical thin layer chromatography (TLC) was performed using glass-backed silica gel 60 F 254 pre-coated plates (Merck Art 5719) and eluted with appropriate solvent ratios (v/v) Reactions were assayed by TLC or LCMS and terminated as judged by the consumption of starting material Visualization of the TLC plates was done with UV light (254 nm wavelength) or with an appropriate TLC visualizing solvent and activated with heat Analytical HPLC performed with Waters or Agilent instruments Flash column chromatography (Still et al , J Org Chem , 1978, 43, 2923) was performed using silica gel 60 (Merck Art 9385) or various MPLC systems, such as Biotage or ISCO purification system Preparative HPLC routinely performed on Prep LC 4000 system from Water with Ultra 120 10 mm C8 column from Peeke Scientific for single compounds, combinational, solution-based samples described in detail herein Microwave chemistry was carried out using an EmrysTM Optimizer EXP from Personal Chemistry, lnc (now Biotage) The compound structures in the examples below were confirmed by one or more of the following methods proton magnetic resonance spectroscopy, mass spectroscopy, and elemental microanalysis Proton magnetic resonance (1H NMR) spectra were determined using a Bruker spectrometer operating at field strength of 300 or 400 megahertz (MHz) Chemical shifts are reported in parts per million (ppm, δ) downfield from an internal tetramethylsilane standard Alternatively, 1H NMR spectra were referenced relative to signals from residual protons in deuterated solvents as follows CDCI3 = 7 25 ppm, DMSO-d6 = 2 49 ppm, CD3CN = 1 94 ppm, CD3OD or methanol-^ = 3 30 ppm, CeD6 = 7 16 ppm Peak multiplicities are designated as follows s, singlet, d, doublet, dd, doublet of doublets, t, triplet, dt, doublet of triplets, q, quartet, br, broadened, m, multiplet Coupling constants are given in Hertz (Hz) Mass spectra (MS) data were obtained using Agilent LC mass spectrometer with APCI or ESI ionization High resolution MS (HRMS) were performed on an Agilent G3250AA LCMSD/TOF mass spectrometer Elemental microanalyses were performed by Atlantic Microlab Inc. and gave results for the elements stated within ±0.4% of the theoretical values.
Preferred compounds in accordance with the invention may be prepared in manners analogous to those specifically described below. The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. The skilled artisan will recognize that different acids, amines, alkyl halides, aryl halides, coupling reagents, and heterocycles may be substituted in the following descriptions to suit the preparations of a desired embodiment. The following methods may be scaled upwards or downwards to suit the amount of desired material.
Scheme A NHNH,
Figure imgf000034_0001
a-8 a-9
Figure imgf000034_0002
a-10
Example A-1
[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 W-1 ,2,4-triazol-3- yl]methyl Nitrate (A-1 )
Figure imgf000034_0003
Step 1 : 3, 4-Difluorobenzenesulfonyl Chloride (a-2)
Figure imgf000034_0004
Chlorosulfonic acid (600 ml_, 8.5 mol) was added slowly to 1 ,2-difluorobenzene (200 g, 1 .76 mol) while maintaining the temperature below 00C. After the addition, the reaction mixture was stirred until gas evolution ceased. Then the reaction mixture was stirred at 11O0C for about 30 hours. TLC (Petroleum ether: EtOAc = 5:1 ) showed that the reaction was complete. Then the reaction mixture was poured into ice with rapid stirring. The resulting mixture was extracted with CH2CI2 (500 ml_χ3). The organic phase was washed with sat. aq. NaHCO3 and sat. aq. NaCI, dried over anhydrous Na2SO4 and concentrated in vacuum to give compound (200 g, 52%) as a brown liquid, which was used in the next step without further purification.
Step 2: 3, 4-Difluorobenzenesulfonamide (a-3)
Figure imgf000035_0001
Through a solution of crude sulfonyl chloride a-2 (200 g, 0.92 mol) in anhydrous CH2CI2 (1.5 L) at -3O0C was bubbled NH3 (g). 10 min later, white syrup was formed. 30 min later, TLC (EtOAc: Petroleum ether = 1 :2) showed that the reaction was complete. The mixture was evaporated in vacuum to give crude compound, which was purified via column chromatography (EtOAc: Petroleum ether = 1 :5-1 :2-1 :0) to give pure compound a-3 (170 g, -92.8%) as a white solid, which was used in next step without further purification. 1H NMR (400 MHz, DMSO): δ 7.82 (t, 1 H), 7.67 (m, 2H), 7.52 (s, 1 H).
Step 3: 3-Fluoro-4-hydrazinylbenzenesulfonamide Hydrochloride (a-4)
Figure imgf000035_0002
To a solution of compound a-3 (200 g, 1.04 mol) in CH3CN (3 L) was added dropwise hydrazine hydrate (85%, 200 mL, 5.3 mol). After the addition, the reaction mixture was heated at reflux (700C) overnight. TLC (CH2CI2: MeOH = 10:1 ) showed that the reaction was complete. CH3CN was evaporated on vacuum. H2O (1.5 L) was added with rapidly stirring and a suspension was formed. The precipitate was filtered to give crude product. The crude product was recrystallized from MeOH. Then the product was poured into a solution of EtOH (500 mL) and saturated with HCI (g) at room temperature. The resulting mixture was stirred at room temperature overnight The mixture was evaporated in vacuum and the crude product was recrystallized from MeOH to give pure hydrazine hydrochloride a-4 (1 10 g, 48 7%) as a light yellow solid that matched that described in literature (Pal, M et al J Med Chem 2003, 46, 3975-3984) 1H NMR (400 MHz, DMSO) δ 10 58 (s, 3H), 8 87 (s, 1 H), 7 57 (s, 1 H), 7 55 (d, 1 H), 7 34 (s, 2H), 7 24 (t 1 H)
Step 4: Cyanomethyl 2-(2,5-Dimethylphenyl)acetate (a-6)
Figure imgf000036_0001
Chloroacetonitrile (0 58 mL 9 3 mmol) was added to a solution of 2-(2,5- dιmethylphenyl)acetιc acid (1 5 g, 9 3 mmol) and di-isopropyl-ethyl-amine (DIPEA, 1 8 mL 10 mmol) in acetonitπle (9 3 mL) The reaction was heated to 8O0C for 1 hour then concentrated by rotary evaporation The residue was suspended in ethyl acetate and washed sequentially with water, aqueous sodium bicarbonate and brine The ethyl acetate layer was dried with magnesium sulfate, filtered and concentrated by rotary evaporation to yield cyanomethyl 2-(2,5-dιmethylphenyl)acetate (a-6, 1 83 g, 97%)
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 2 25 (s, 3 H), 2 30 (s, 3 H), 3 68 (s, 2 H), 4 71 (s, 2 H), 6 99 (s, 1 H), 7 00 - 7 03 (m, 1 H), 7 04 -7 10 (m, 1 H) LCMS (M+H)+ 220 1
Step 5: 2-Ethoxy-2-iminoethyl 2-(2,5-dimethylphenyl)acetate Hydrochloride (a-7)
Figure imgf000036_0002
HCI gas was bubbled into a O0C mixture of cyanomethyl 2-(2,5-dιmethylphenyl)acetate (a-6 1 83 g 9 0 mmol) ethanol (0 58 mL, 9 9 mmol) and diethylether (1 8 mL) for 3 minutes After 15 minutes more diethylether (6 mL) was added After an additional 20 minutes the cooling bath was removed and the reaction was allowed to warm to room temperature The reaction was filtered to afford 2-ethoxy-2-ιmιnoethyl 2-(2,5- dιmethylphenyl)acetate hydrochloride (a-7, 2 29 g), which was used without further purification 1H NMR (400 MHz, DMSO-c/6) δppm 1.30 (t, J=6.95 Hz, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 3.82 (s, 2 H), 4.43 (q, J=6.91 Hz, 2 H), 4.98 (s, 2 H), 7.00 (d, J=7.83 Hz, 1 H), 7.03 (s, 1 H), 7.04 - 7.09 (m, 1 H) LCMS (M+H)+: 220.1.
Step 6: 4-[5-2, 4-Dimethylbenzyl-3-(hydroxymethyl)-1H-1 ,2,4-triazol-1-yl]-3- fluorobenzenesulfonamide (a-8)
Figure imgf000037_0001
To a 1 L round bottom was added crude 2-ethoxy-2-iminoethyl 2-(2,5- dimethylphenyl)acetate hydrochloride (a-7; 28.0 g, -73.5 mmol), 3-fluoro-4- hydrazinylbenzenesulfonamide hydrochloride (a-4; 17.8 g, 73.5 mmol), pyridine (400 ml_) and 4A, 8-12 mesh molecular sieves (13.2 g). A nitrogen inlet was added and the mixture was evacuated and filled with nitrogen three times. The mixture was heated to 7O0C for one hour than heated to 8O0C overnight. The reaction was concentrated by rotary evaporation and the residue was partitioned between ethyl acetate and water. The aqueous layer was adjusted to pH 1 with 1 M HCI. The layers were separated and the ethyl acetate layer was washed with brine then dried with magnesium sulfate, filtered and concentrated by rotary evaporation. The crude material was suspended in 30 ml_ of boiling ethanol and left standing overnight. The suspension was diluted with 30 ml_ of etherethanol (9:1 ), filtered and washed with etheπethanol (9:1 ) to give 4-(5-(2,5- dimethylbenzyl)-3-(hydroxymethyl)-1 H-1 ,2,4-triazol-1-yl)-3-fluorobenzenesulfonamide (a-8; 18.2 g).
1H NMR (400 MHz, DMSO-c/6) δ ppm 2.03 (s, 3 H), 2.12 (s, 3 H), 4.01 (s, 2 H), 4.44 (d, J=6.32 Hz, 2 H), 5.39 (t, J=6.06 Hz, 1 H), 6.63 (s, 1 H), 6.86 - 6.91 (m, 1 H), 6.93 - 7.00 (m, 1 H), 7.70 (S1 2 H), 7.76 - 7.82 (m, 2 H), 7.82 - 7.87 (m, 1 H) LCMS (M+H)+: 391.1 . Step 7: 4-[3-(Chloromethyl)-5-(2,5-dimethylbenzyl)-1 W-1 ,2,4-triazol-1 -yl]-3- fluorobenzenesulfonamide (a-9)
Figure imgf000038_0001
A mixture of 4-[5-(2,5-dimethylbenzyl)-3-(hydroxynriethyl)-1H-1 ,2,4-triazol-1-yl]-3-fluoro- benzene-sulfonamide (1 0 g, 2.6 mmol) in thionyl chloride (30 ml_, 240 mmol) was stirred at room temperature for 2 hours then concentrated to dryness. The residue was treated with toluene (25 mL) and concentrated to dryness. The residue was placed under high vacuum for 2 hours to remove any residual thionyl chloride to give the title compound (1 1 g, 99 %) as a light brown oil, which was used in the next step without further purification LCMS (M+H)+ 409 2.
Step 8: 4-[5-(2,5-dimethylbenzyl)-3-(iodomethyl)-1 W-1 ,2,4-triazoM -yl]-3- fluorobenzenesulfonamide (a-10)
Figure imgf000038_0002
To a mixture of 4-[3-(chloromethyl)-5-(2,5-dιmethylbenzyl)-1 /-/-1 ,2,4-tιϊazol-1 -yl]-3-fluoro- benzene-sulfonamide (a-9, 1 1 g, 2 6 mmol) in tetrahydrofuran (30 mL) was added sodium iodide (1 9 g, 13 mmol) The mixture was stirred at room temperature for 1 hour Solids were filtered off and the filtrate concentrated to dryness. The residue was dissolved in EtOAc (75 mL), washed with 10 % aqueous Na2S2Os, water, and brine. The organic layer was dried over MgSO4, filtered, and concentrated to give the title compound (1 29 g, 99 %) as a light brown oil, which was used in the next step without further purification LCMS (M+H)+ 501 0 Step 9: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 HA ,2,4- triazol-3-yl]methyl Nitrate (A-1 )
Figure imgf000039_0001
To a mixture of 4-[5-(2,5-dimethyl-benzyl)-3-(iodomethyl)-1 /-/-1 ,2,4-triazol-1-yl]-3-fluoro- benzene-sulfonamide (a-10; 0.81 g, 1.6 mmol) in acetonitrile (19 mL) and N, N- dimethylformamide (19 mL) was added silver nitrate (1.2 g, 7.3 mmol). The mixture was stirred at 8O0C for 4 hours. After cooling to ambient temperature, brine was added (20 mL), the mixture sonicated, solids filtered and washed with acetonitrile, and filtrate concentrated to dryness. The residue was purified by chromatography with silica gel and elution with a gradient of ethyl acetate/hexanes (12-100 %) to give the title compound (0.59 g, 83 %) as a white solid.
1H NMR (300 MHz, DMSOd6): δ 2.03 (s, 3 H), 2.13 (s, 3 H), 4.07-4.14 (m, 2 H), 5.69- 5.74 (m, 2 H), 6.64 (m, 1 H), 6.88-7.02 (m, 2 H), 7.70-7.91 (m, 5 H). LCMS (M+H)+: 436.2.
Scheme B
Figure imgf000039_0002
a-8 b-1
Figure imgf000039_0003
B-1 [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4-triazol-3- yljmethyl 6-Bromo-hexanoate (b-1 )
Figure imgf000040_0001
To alcohol a-8 (250 mg, 0.640 mmol) in dichloromethane (5 ml_) was added sequentially DMA (1 ml_) and 2-chloropyridine (70 uL, 0.75 mmol), then cooled to 00C. 6- Bromohexanoyl chloride (86 uL; 0.56 mmol) was added portionwise and the cooling bath was removed. TLC with 20% EtOAcZCH2Cb showed little reaction after 4 hours, and more 6-bromohexanoyl chloride (20 uL) added. After stirring overnight, the LC/MS shows - 20% product. Cooled to 0 C and added more chloropyridine (89 uL) and more 6-bromohexanoyl chloride (80 uL). Let stir for 30 minutes at 00C and allowed to warm to ambient temperature. After 30 minutes, LC/MS monitored, cooled to 00C and added chloropyridine (189 uL) and acid chloride (180 uL). After 3.5 hours LC/MS indicated completion. Diluted with more dichloromethane and washed with water. Concentrated and chromatography with 10-50% EtOAc/dichloromethane eluent gave 210 mg of clear oil (-58%), which was used without further purification.
1 H NMR (400 MHz, CHLOROFORM-d) δ 1.50 (m, 2 H), 1.60 b(s, 3 H), 1 .65 - 1.77 (m, 2 H), 1 .83 - 1 .92 (m, 2 H), 2.06 (s, 3 H), 2.16 (s, 3 H), 2.44 (t, J=7.5 Hz, 2 H), 3.39 (t, J=6.8 Hz, 2 H), 4.08 (s, 2 H), 5.03 (s, 2 H), 5.23 (s, 2 H), 6.60 (s, 1 H), 6.88-6.96 (m, 2 H), 7.40 m, 1 H), 7.71 -7.77 (m, 2 H). LC/MS APCI m/z 567
[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4-triazol-3- yl]methyl 6-(Nitro-oxy)-hexanoate (B-1 )
Figure imgf000040_0002
To 4-(5-(2,5-dimethylbenzyl)-3-(hexanoylbromideoxymethyl)-1 H-1 ,2,4-triazol-1 -yl)-3- fluoro-benzene-sulfonamide (b-1 ; 210 mg; 0.370 mmol) in acetonitrile (2 mL) in a reaction vessel covered in foil was added silver nitrate (250 mg, 1.47 mmol). After 5 hours at ambient temperature, the mixture was diluted with CH2CI2 and washed with water and brine. Concentration followed by trituration with diethyl ether gave 210 mg of a white solid in quantitative yield.
1H NMR (400 MHz, CHLOROFORM-tf) δ 1.42-1.53 (m, 2 H), 1.67-1.78 (m, 4 H), 2.05 (s,
3 H), 2.16 (s, 3 H), 2.44 (t, J=7.3 Hz, 2 H), 4.07 (s, 2 H), 4.42 (t, J=6.6 Hz, 2 H), 5.10 (s,
2 H), 5.23 (s, 2 H), 6.60 (s, 1 H), 6.88-6.96 (m, 2 H), 7.35-7.41 (m, 1 H), 7.70-7.77 (m, 2
H).
LC/MS APCI m/z 550
Other examples B-2, B-3 were prepared in similar fashion to B-1 and their respective analytical data is furnished in Table 1.
Scheme C
Figure imgf000041_0001
Step 1 : 2-(2-Chloroethoxy)acetic Acid (c-2) o
HO ^^ ^^ Cl
To concentrated H2SO4 (6 ml_) was added CrO3 ( 4 g, 40.1 mmol). To this mixture ice water (15 mL), was added dropwise. Once all the material was dissolved, the solution was added dropwise to 5 g of silica gel while stirring. To the adsorbed Jones's reagent, 50 mL of DCM were added and the mixture was cooled to 0 0C. A solution of the alcohol (1.00 g, 8.03 mmol), was added dropwise and stirred for 30 min. The reaction was filtered and the silica cake was washed with DCM (100 mL). The solvent was removed and the residue was fractioned between ether (3 x 20 mL), and 10 % aqueous K2CO3 (3 x 50 mL). The organic layer was discarded and the aqueous layer was taken to pH=1 with aqueous 3 N HCI. The aqueous layer was saturated with Na2SO4 and extracted with MeCN. The organic layer was concentrated and the residue dissolved in 50 mL of DCM. The solution was dried over Na2SO4 and concentrated to give 0.8 g of a colorless oil, which was used without further purification. 1H NMR (400 MHz, DMSO-c/6): δ 3.73 (s, 4 H), 4.07 (s, 2 H), 12.72 (br s., 1 H).
Step 2: 2-(2-Chloroethoxy)acetyl Chloride (c-3) o
Cl ^" ^ Cl
To the acid, oxalyl chloride (50 mL), was added. The reaction was stirred at room temperature for 8 h. The solids were filtered and washed with DCM. The volatiles were removed and to give the product (560 mg), as a light yellow oil, which was used without further purification.
1H NMR (400 MHz, CHLOROFORM-c/), δ ppm 3.67 (t, J=5.5 Hz, 2 H), 3.88 (t, J=5.7 Hz, 2 H), 4.52 (s, 2 H).
Step 3: [1 -[4-(Aminosulfonyl)-2-f!uorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl (2-Chloroethoxy)acetate (c-4)
Figure imgf000043_0001
Similar to step 1 of Scheme B; the esterification to b-1. To a solution of the alcohol a-8 (350 mg, 0.896 mmol), in CH2CI2 (20 ml_)/DMA (2 mL), and 2-chloropyridine, (0.505 ml_,
5.38 mmol); a solution of the acid chloride c-3 (560 mg, 3.56 mmol), in DCM (20 mL), was added at O0C. The solution was stirred at room temperature for 4 h. The volatiles were removed and the product was purified by column chromatography to give the product as a light yellow oil. (350 mg, 85 %), which was used without further purification. LC-MS (M+1 ), = 51 1 AMU.
1H NMR (400 MHz, MeOD), δ ppm 2.02 (s, 3 H), 2.12 (s, 3 H), 3.28-3.33 (m, 2 H), 3.68 (t, J=8.0 Hz, 2 H), 3.81 (t, J=8 Hz, 2 H), 4.13 (s, 2 H), 5.26 (s, 2 H), 6.57 (s, 1 H), 6.90 (s, 2 H), 7.59 (s, 1 H), 7.76 (s, 2 H).
Step 4: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl (2-lodoethoxy)acetate (c-5)
Figure imgf000043_0002
To a solution of the chloride (350 mg, 0.631 mmol), in acetone (50 mL), NaI was added (1 g, 6.67 mmol). The mixture was sonicated until all the salts dissolved and heated to 65 0C for 8 h. The volatiles were removed and the residue was fractioned between water and DCM (3 x 50 mL). The organics were dried over Na2SO4 and evaporated to dryness to give the product as a light yellow solid, which was used without further purification. LC-MS (M+1 ), = 603 AMU 1H NMR (400 MHz, MeOD), δ ppm 2.03 (s, 3 H), 2.12 (s, 3 H), 3.79 (t, J=6.67 Hz, 2 H), 3.84-3.88 (m, 2 H), 4.08 (s, 2 H), 4.11 (s, 2 H), 4.44 (s, 2 H), 6.57 (s, 1 H), 6.84-6.91 (m, 1 H), 6.90-6.98 (m, 1 H), 7.63 (m, 1 H), 7.77 (s, 2 H).
Step 5: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]methyl [2-(Nitrooxy)ethoxy]acetate (C-1 )
Figure imgf000044_0001
To a solution of the iodide (380 tng, 0.631 mmol), in MeCN (50 ml_), was added AgNO3 (430 mg, 2.52 mmol). The solution was stirred at room temperature for 8 h. The volatiles were removed and the residue was fractioned between water and EtOAc (3 x 50 ml_). The organic layer was dried over Na2SO4 and evaporated. The residue was dissolved in MeCN/water 1 :1 (10 ml_), and freeze-dried to give the product as a white solid (325 mg, 95 %).
Exact mass: Calculated for C22H24FN5O8S :538.14 (M+1 ); Measured= 538.13998.
1H NMR (400 MHz, DMSO-d6), δ ppm 2.03 (s, 3 H), 2.11 (s, 3 H), 3.76-3.85 (m, 2 H), 4.05 (s, 2 H), 4.25 (s, 2 H), 4.54-4.75 (m, 2 H), 5.18 (s, 2 H), 6.61 (s, 1 H), 6.83-6.93 (m,
1 H), 6.92-7.02 (m, 1 H), 7.70 (s, 2 H), 7.82 (m, 3 H).
Scheme D
Figure imgf000045_0001
step 4 NaI
Figure imgf000045_0002
Step 1 : 2-(2-(2-Chloroethoxy)ethoxy)acetic Acid (d-2)
Figure imgf000045_0003
C1O3 (5.3 g, 40.1 mmol) was dissolved in 8 ml_ of H2SO4, and added to 25 mL of ice water dropwise. Once all the material was dissolved, the solution was added dropwise to 5 g of silica gel while stirring. To the adsorbed Jones's reagent, 50 mL of DCM was added and the mixture was cooled to O0C. A solution of alcohol a-8 (3g, 17.79 mmol) was added dropwise (the orange mixture turned dark-green), and stirred for 30 min. The reaction was filtered and the silica cake was washed with DCM (100 mL) The solvent was removed and the residue was fractioned between ether (3 x 20 mL), and 10 % aqueous K2CO3 (3 x 50 mL) The organic layer was discarded and the aqueous layer was taken to pH=1 with aqueous 3 N HCI The aqueous layer was saturated with Na2SO4 and extracted with MeCN The organic layer was concentrated and the residue dissolved in 50 mL of DCM The solution was dried over Na2SO4 and concentrated to give 0 8 g of a colorless oil, which was used without further purification
1H NMR (400 MHz, DMSO-d6), δ ppm 3 43-3 50 (m, 4 H), 3 72 (t, J=5 54 Hz, 2 H), 4 06- 4 1 1 (m, 2 H), 4 18 (t, J=4 Hz, 2 H)
Step 2: 2-(2-(2-Chloroethoxy)ethoxy)acetyl Chloride (d-3)
Figure imgf000046_0001
Thionyl chloride (5 mL), was added to the acid and the reaction was stirred at room temperature for 2 h The solids were filtered and washed with DCM The volatiles were removed to give the product as light yellow oil (560 mg), which was used for the next step as obtained
Step 3. [1 -[4-(Amιnosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]methyl [2-(2-Chloroethoxy)ethoxy]acetate (d-4)
Figure imgf000046_0002
Similar to step 1 of Scheme B esterification to b-1 To a solution of the alcohol (350 mg, 0 896 mmol), in CH2CI2 (20 mL)/DMA (2 mL), and 2-chloropyrιdιne, (0 505 mL, 5 38 mmol) a solution of the acid chloride, (560 mg, 2 79 mmol), in DCM (20 mL), was added at O0C The solution was stirred at room temperature for 4 h The volatiles were removed and the product was purified by column chromatography to give the product as a light yellow oil (350 mg, 85 %), that was used without further purification.
LC-MS (M+1 ), = 556 AMU.
Step 4: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]methyl [2-(2-lodoethoxy)ethoxy]acetate (d-5)
Figure imgf000047_0001
To a solution of the chloride (350 mg, 0.631 mmol), in acetone (50 ml_) was added NaI (1 .00 g, 6.67 mmol). The mixture was sonicated until all the salts dissolved and heated to 65 0C for 8 h. The volatiles were removed and the residue was fractioned between water and DCM (3 x 50 ml_). The organics were dried over Na2SO4 and evaporated to dryness to give 230 mg of a light yellow oil, which was used without further purification. LC-MS (M+1 ), = 647 AMU.
1H NMR (400 MHz, MeOD), δ ppm 2.02 (s, 3 H), 2.12 (s, 3 H), 3.18-3.29 (m, 2 H), 3.66 (s, 2 H), 3.69-3.78 (m, 4 H), 4.13 (s, 2 H), 4.28 (s, 2 H), 5.27 (s, 2 H), 6.56 (s, 1 H), 6.82- 6.89 (m, 1 H), 6.89-6.96 (m, 1 H), 7.51-7.60 (m, 1 H), 7.71-7.84 (m, 2 H).
Step 5: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H- 1 ,2,4- tιϊazol-3-yl]methyl {2-[2-(Nitrooxy)ethoxy]ethoxy}acetate (D-1)
Figure imgf000047_0002
To a solution of the iodide (230 mg, 0.356 mmol), in MeCN (20 ml_), AgNO3 (242 mg, 1.42 mmol), was added and the solution was heated to 6O0C for 1 h. Another 4 equivalents of AgNO3 were added and heated for another hour. The volatiles were removed and the residue was fractioned between water and ethyl acetate (3 x 20 ml_). The organic layer was dried over Na2SO4 and evaporated to dryness to give 130 mg of the product as colorless oil.
LC-MS (M+1 )= 582.1 (100 %).
HRMS calculated for C24H28FN5O9S: 581.15918, Found (M+1 ), = 582.16694.
1H NMR (400 MHz, DMSO-d6), δ ppm 2.02 (s, 3 H), 2.11 (s, 3 H), 3.58 (m, 4 H), 3.71 (m, 2 H), 4.06 (s, 2 H), 4.17 (s, 2 H), 4.57-4.69 (m, 2 H), 5.18 (s, 2 H), 6.61 (s, 1 H), 6.89 (m, 1 H), 6.93-7.00 (m, 1 H), 7.71 (s, 2 H), 7.82 (m, 3 H).
Scheme E
Figure imgf000048_0001
E-1 Step 1 : 4-[(Nitrooxy)methyl]benzoic Acid (e-2)
Figure imgf000049_0001
To a slurry of 4-(bromomethyl)benzoic acid (500 mg, 2.33 mmol) in acetonitrile (10 ml_) was added silver(l) nitrate (474 mg, 2.79 mmol) in one portion. The suspension was allowed to stir at 230C for 12 h. The slurry was then vacuum filtered through a pad of Celite and concentrated in vacuo to provide the title compound as a white solid (361 mg, 79%), which was used without further purification.
1H NMR (300 MHz, DMSO-Cf6) δ ppm 13.09 (br s, 1 H) 7.98 (d, J=8.3 Hz, 2 H) 7.57 (d, J=7.9 Hz, 2 H) 5.65 (s, 2 H)
Step 2: 4-(1 tf-lmidazol-1 -ylcarbonyl)benzyl Nitrate (e-3)
Figure imgf000049_0002
To a solution of 4-[(nitrooxy)methyl]benzoic acid (e-2; 210 mg, 1.07 mmol) in dichloromethane (10 ml_) under nitrogen was added 1 ,1-carbonyldiimidazole (173 mg, 1.07 mmol) in one portion. The flask was purged with nitrogen and allowed to stir at 23 0C for 30 min. This solution was used as is for the following step.
Step 3: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 4-[(nitrooxy)methyl] Benzoate (E-1 )
Figure imgf000049_0003
Using a method described by Greenwald, R B , et al, J Org Chem 1998, 63, 7559- 7562 to a solution of the alcohol (a-8, 208 mg, 0 533 mmol) in dichloromethane (10 mL) and N,N-dιmethyl-acetamιde (1 mL) was added N,N-dιmethylamιnopyrιdιne (13 mg, 0 1 1 mmol) and scandιum(lll) triflate (26 mg, 0 053 mmol) sequentially The flask was purged with nitrogen and the solution was cooled to O0C in an ice bath After 10 mm a solution of 4-(1 /-/-ιmιdazol-1 ylcarbonyl)benzyl nitrate (e-3) (10 mL, 1 07 mmol) was added in one portion The solution was then allowed to warm to 230C and stirred for 48 h The solution was then diluted with dichloromethane (25 mL) and sequentially washed with aqueous sodium bisulfate (1 N, 20 mL), deionized water (20 mL), and brine (20 mL) The organic layer was then dried (Na2SO4), filtered and concentrated in vacuo The crude solid was then purified by preparative reverse phase high performance liquid chromatography (40-90% MeCN/H2O, 0 1 % AcOH) The eluant was lyophihzed to dryness to provide the title compound as a white solid (154 mg, 50%)
1H NMR (300 MHz, DMSO-d6) δ 8 03 (s, 1 H), 8 00 (s, 1 H), 7 74 - 7 90 (m, 3 H), 7 69 (br s 2 H) 7 64 (s 1 H) 7 61 (s, 1 H), 6 96 (d, J=7 6 Hz, 1 H), 6 88 (d, J=7 8 Hz, 1 H), 6 59 (s, 1 H), 5 67 (s, 2 H), 5 41 (s, 2 H), 4 06 (s, 2 H), 2 09 (s, 3 H), 2 02 (s, 3 H)
LC-MS (ESI), [M - H] = 568 0
Scheme F-1
Figure imgf000051_0001
Step 1 : Methyl 2,2-Dimethyl-3-(nitrooxy)propanoate (f-2)
Figure imgf000051_0002
To acetic anhydride (2.9 mL, 30.3 mmol), in methylene chloride at O0C was added fuming nitric acid in 10 mL methylene chloride over 0.2 h, then stirred for 1 h. Added methyl 3-hydroxy-2,2-dimethylpropanoate (2.5 g, 18.9 mmol), in 1 mL of methylene chloride over 0.1 h. After 1 h, quenched with 20 g of ice then added 30 mL CH2CI2 and partitioned with sat. NaHCO3 (2 X 20 mL), and dried organic over Na2SO4. The organic layer was concentrated to afford product as a clear oil (2.54 g, 76%), which was used without further purification. 1H NMR (400 MHz, CHLOROFORM-c/), δ ppm 4.48 (s, 2 H), 3.71 (s, 3 H), 1.28 (s, 6 H). Step 2: 2,2-Dimethyl-3-(nitrooxy)propanoic Acid (f-3)
Figure imgf000052_0001
To methyl 2,2-dimethyl-3-(nitrooxy)propanoate (f-2; 1.3 g, 7.2 mmol), in methanol was added aq. sodium hydroxide solution (4.3 ml. of 2N, 8.6 mmol). Allowed to stir for 2 hours, then concentrated to give white crystalline solid, which was dissolved in 20 mL methylene chloride and partitioned between aq. HCI (30 mL of 0.5 N). Separated organic layer dried over Na2SO4 then concentrated to afford product as a white solid (1.34 g, 80%), which was used without further purification. 1H NMR (400 MHz, CHLOROFORM-d), δ ppm 4.53 (s, 2 H), 1.34 (s, 6 H).
Step 3: 3-Chloro-2,2-dimethyl-3-oxopropyl Nitrate (f-4)
Figure imgf000052_0002
To nitrate ester f-3 (1.0 g, 6.1 mmol), in methylene chloride (10 mL), was added oxalyl chloride (0.82 mL, 9.2 mmol), and 0.05 mL of DMF. After 2 hours, concentrated under reduced pressure and the residue was azeotroped with toluene (2 X 4 mL), to afford product as a clear oil (0.56 g, 91 %), which was used without further purification. 1H NMR (400 MHz, CHLOROFORM-d), δ ppm; 4.58 (s, 2H), 1.43 (s, 6H).
Step 4: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 2,2-Dimethyl-3-(nitrooxy)propanoate (F-1 )
Figure imgf000052_0003
Prepared in a fashion similar to that of d-4, from 4-[5-2, 4-dimethylbenzyl-3- (hydroxymethyl)-1 H-1 ,2,4-triazol-1-yl]-3-fluorobenzenesulfonamide (a-8; 1.10 g, 2.82 mmol), in DMA with 2-chloro pyridine and crude acid chloride f-4. Allowed to stir for 24 h at 6O0C. Diluted with EtOAc (100 mL), and partitioned between HCI aq. (2 X 50 mL, 1 N), CuSO4 (2 x 25 mL, 10 % w/v), and NaHCO3 (2 X 50 mL). The organic layer was dried over Na2SO4 and concentrated to give a clear oil. Purification with chromatography with silica gel eluting with EtOAc/Hexane (1 :1 ). The residue was dissolved in EtOAc and added hexane to crystallize product as a white solid after drying under vacuum for 24 hours (1.43 g, 94%). 1H NMR (400 MHz, CHLOROFORM-d), δ ppm; 7.74 (t, 2 H), 7.40 (t, J=7.8 Hz, 1 H), 6.85 - 6.98 (m, 2 H), 6.61 (s, 1 H), 5.27 (s, 2 H), 4.54 (s, 2 H), 4.04 (s, 2 H), 2.16 (s, 3 H), 2.04 (s, 3 H), 1.32 (s, 6 H). LC/MS APCI m/z 433.1 .
HRMS (ESI): Calcd for C23H27FN5O7S m/z: 536.1615, Found: 536.3210. Anal Calcd for C23H26FN5O7SOJ EtOAc: C, 51 .89; H, 5.33; N, 1 1.73; Found: C, 51.91 ; H, 5.16; N, 1 1 .61.
Figure imgf000053_0001
Step 1 : [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl /V-(tert-butoxycarbonyl), L-Valinate (g-1 )
Figure imgf000054_0001
To a solution of 4-[3-(chloromethyl)-5-(2,5-dιmethyl-benzyl)-1 /-/-1 ,2,4-tπa-zol-1-yl]-3- fluoro-benzene-sulfonamide (a-9, 400 mg, 0 987 mmol), in DMF (3 ml_), was added sequentially BOC-L-valine (638 mg, 2 93 mmol), crushed K2CO3 (419 mg, 3 03 mmol), and Kl (16 mg, 0 0978 mmol) The mixture stirred for 16 h, then heated to 600C, and stirred for 2 h The mixture was cooled to ambient temperature, diluted with EtOAc (50 ml_), washed with H2O (3 x 25 ml_), and brine (25 ml_), dried over Na2SO4, filtered, and concentrated under reduced pressure The crude residue was purified by column chromatography (25 - 60% EtOAc/hexanes), to give 1-[4-(amιnosulfonyl)-2- fluorophenyl]-5-(2,5-dιmethylbenzyl)-1 H-1 ,2,4-trιazol-3-yl]methyl N-(tert- butoxycarbonyl)-L-valιnate (437 mg, 74%), as a white solid, which was used without further purification 1H NMR (400 MHz, CHLOROFORM-tf), δ ppm 7 71 - 7.79 (m, 2 H), 7.36 - 7.42 (m, 1 H), 6 95 (d, J=I 58 Hz, 1 H), 6 90 (d, J=I 58 Hz, 1 H), 6 60 (s, 1 H), 5 22 - 5 37 (m, 2 H), 5 07 (d, J=8 59 Hz, 1 H), 5 01 (s, 2 H), 4 34 (dd, J=8 84, 3 79 Hz, 1 H), 4 07 (s, 2 H), 2 17 - 2 28 (m, 1 H), 2 16 (s, 3 H), 2 05 (s, 3 H), 1 45 (s, 9 H), 0 97 (d, J=S 82 Hz, 3 H), 0 88 (d, J=Q 82 Hz, 3 H) LC/MS ESI m/z (M+H)+ 590 2
Step 2: [1 -[4-(Aminosulfonyl)-2-fIuorophenyl]-5-(2,5-dimethylbenzyl)-1 HA ,2,4- triazol-3-yl]methyl L-Valinate (g-2)
Figure imgf000055_0001
To a solution of the BOC-amine g-1 (437 mg, 0.741 mmol), in CH2CI2 (2.5 ml_), was added TFA (0.571 mL, 7.41 mmol). The reaction mixture was stirred for 4h, quenched with saturated aq. NaHCO3 (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under vacuum. [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5- dimethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]methyl L-valinate (237 mg, 65% yield), was obtained as a white foam and carried to the next step without purification.
1H NMR (400 MHz, CHLOROFORM-d), δ ppm 7.70 - 7.80 (m, 2 H), 7.36 - 7.42 (m, 1 H), 6.95 (d, J=7.58 Hz, 1 H), 6.90 (d, J=7.83 Hz, 1 H), 6.60 (s, 1 H), 5.26 - 5.37 (m, 2 H), 4.99 (s, 2 H), 4.02 - 4.09 (m, 3 H), 2.24 - 2.37 (m, 1 H), 2.16 (s, 3 H), 2.05 (s, 3 H), 1.04 (d, J=6.82 Hz, 3 H), 0.90 (d, J=6.82 Hz, 3 H). LC/MS ESI m/z (M+H)+ 490.2.
Step 3: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 HA ,2,4- trϊazol-3-yl]methyl Λ/-(4-bromobutanoyl), L-Valinate (g-3)
Figure imgf000055_0002
Amine g-2 (324 mg, 0.662 mmol), was dissolved in CH3CN (3.3 mL), and 2- chloropyridine (0.188 mL, 1 .99 mmol), and cooled to O0C. 4-Bromobutyryl chloride
(0.230 mL, 1.99 mmol), was added and allowed to warm to ambient temperature. After 3h, more 4-bromobutyryl chloride (0.080 mL), was added and stirred for another 1.5 h. The reaction mixture was diluted with EtOAc (50 mL), and washed with H2O (2 x 30 mL), 1 N HCI (30 mL), and brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography (35 - 80% EtOAc/hexanes), to obtain [1 -[4-(aminosulfonyl)-2-fluorophenyl]-5-(2,5- dimethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]methyl Λ/-(4-bromobutanoyl)-L-valinate (286 mg, 68% yield), as a white solid, which was used without further purification. 1H NMR (400 MHz, CHLOROFORM-c/), δ ppm 7.72 - 7.79 (m, 2 H), 7.37 - 7.43 (m, 1 H), 6.94 - 6.97 (m, 1 H), 6.88 - 6.93 (m, 1 H), 6.61 (s, 1 H), 6.09 (d, J=8.6 Hz, 1 H), 5.23 - 5.36 (m, 2 H), 5.02 (s, 2 H), 4.69 (dd, >8.8, 4.6 Hz, 1 H), 4.06 (s, 2 H), 3.41 - 3.54 (m, 2 H), 2.44 (t, J=6.8 Hz, 2 H), 2.17 - 2.30 (m, 3 H), 2.17 (s, 3 H), 2.05 (s, 3 H), 0.96 (d, J=IA Hz, 3 H), 0.91 (d, J=6.8 Hz, 3 H). LC/MS ESI m/z (M+H)+ 639.0.
Step 4: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl Λ/-[4-(nitrooxy)butanoyl] L-Valinate (G-1 )
Figure imgf000056_0001
Silver nitrate (350 mg, 2.06 mmol), was added to a solution of bromide g-3 (350 mg, 0.688 mmol), in CH3CN (5 mL), and THF (2 mL). The reaction mixture was heated at 600C in the dark. After 1 h, the mixture was allowed to cool to ambient temperature, and then brine (1 mL), H2O (1 mL), and CH2CI2 (1 mL), were added. The precipitate was filtered off. The filtrate was diluted with H2O (50 mL), and extracted with CH2CI2 (3 x 50 mL). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The yellow residue was purified by column chromatography (45 - 75% EtOAc/hexanes), to obtain [1-[4-(aminosulfonyl)-2- f!uorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]methyl N-[A-
(nitrooxy)butanoyl]-L-valinate (171 mg, 49% yield), as a white solid. 1H NMR (400 MHz, CHLOROFORM-d), δ ppm 7.68 - 7.82 (m, 2 H), 7.40 (t, J=7.6 Hz, 1 H), 6.96 (d, J=7.8 Hz, 1 H), 6.91 (d, J=8.1 Hz, 1 H), 6.61 (s, 1 H), 6.10 (d, J=8.8 Hz, 1 H), 5.23 - 5.37 (m, 2 H), 5.02 (s, 2 H), 4.69 (dd, J=8.8, 4.80 Hz, 1 H), 4.52 (t, J=6.2 Hz, 2 H), 4.06 (s, 2 H), 2.38 (t, J=7.1 Hz, 2 H), 2.20 - 2.30 (m, 1 H), 2.17 (s, 3 H), 2.05 (s, 3 H), 2.04 - 2.14 (m, 2 H), 0.95 (d, J=6.8 Hz, 3 H), 0.90 (d, J=6.8 Hz, 3 H).
LC/MS ESI m/z (M+H)+ 621.2.
Scheme H
Figure imgf000057_0001
h-2 H-1
Step 1 : [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl 4-nitrophenyl Carbonate (h-1 )
Figure imgf000057_0002
To a 0°C solution of the alcohol a-8 (500 mg, 1.28 mmol), in 2-chloropyridine (0.727 mL, 7.68 mmol), and CH3CN (6 mL), was added 4-nitrophenyl chloroformate (1.29 mg, 6.40 mmol), and stirred for 1 h. The mixture was allowed to warm to ambient temperature and stir for 2h. EtOAc (50 ml), was added to the mixture, washed with water (30 mL), 1 N HCI (30 mL), and brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (10 - 50% EtOAc/hexanes), to obtain [1-[4-(aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)- 1 H-1 ,2,4-triazol-3-yl]methyl 4-nitrophenyl carbonate (430 mg, 60%), as a clear oil, which was typically used without further purification.
1H NMR (400 MHz, CHLOROFORM-d), δ ppm 8.27 - 8.31 (m, 2 H), 7.74 - 7.82 (m, 2 H), 7.39 - 7.45 (m, 3 H), 6.97 (d, J=7.6 Hz, 1 H), 6.92 (d, J=8.3 Hz, 1 H), 6.63 (s, 1 H), 5.43 (s, 2 H), 5.00 (s, 2 H), 4.09 (s, 2 H), 2.17 (s, 3 H), 2.07 (s, 3 H). LC/MS ESI m/z (M+H)+ 556.0.
Step 2: [1 -[4-(Aminosu!fonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazo!-3-yl]methyl 2-(2-hydroxyethoxy)ethyl Carbonate (h-2)
Figure imgf000058_0001
Similar to the preparation of Example E-1 and method cited therein; a solution of diethylene glycol (0.296 mL, 3.10 mmol), scandium (III) triflate (122 mg, 0.248 mmol), and DMAP (253 mg, 2.07 mmol), in CH2CI2 (1.5 mL), was cooled to 00C and stirred for
30 min. A suspension of the p-nitrophenyl carbonate h-1 (576 mg, 1.03 mmol), in
CH2CI2 (3 mL), was added to the reaction mixture and warmed to ambient temperature.
After 4 h, the mixture was diluted with water (50 mL), and extracted with CH2CI2 (2 x 50 mL). The combined organic layers were washed with 0.1 N aq. HCI (50 mL), and brine
(50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (35-100% EtOAc/Hex), to obtain [1-[4-
(aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]methyl 2-(2- hydroxyethoxy)ethyl carbonate as a clear oil (206 mg, 38% yield), which was used without further purification.
1H NMR (400 MHz, CHLOROFORM-d), δ ppm 7.69 - 7.78 (m, 2 H), 7.35 - 7.41 (m, 1 H), 6.94 (d, J=7.6 Hz, 1 H), 6.89 (d, J=7.6 Hz, 1 H), 6.60 (s, 1 H), 5.30 (s, 2 H), 5.17 (s, 2 H), 4.33 - 4.39 (m, 2 H), 4.07 (s, 2 H), 3.73 - 3.77 (m, 2 H), 3.69 - 3.73 (m, 2 H), 3.58 3.62 (m, 2 H), 2.16 (s, 3 H), 2.05 (s, 3 H). LC/MS ESI m/z (M+H)+ 523.0.
Step 3: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1,2,4- triazol-3-yl]methyl 2-[2-(nitrooxy)ethoxy]ethyl Carbonate (H-1 )
Figure imgf000059_0001
To a solution of the alcohol h-2 (206 mg, 0.380 mmol), in CH2CI2 (2 ml), was added tetraethylammonium nitrate (205mg, 0.392 mmol), and 2,6-di-tert-butyl-4-methylpyridine (121 mg, 0.588 mmol). The reaction stirred at -78°C and a solution of trifluoromethanesulfonic anhydride (0.0693 ml, 0.412 mmol), in methylene chloride (0.5 ml_), was slowly added. After 1 h the temperature rose to ambient temperature and the mix was concentrated in vacuo. The residue was purified by flash chromatography (50% EtOAc/hexane), to obtain [1-[4-(aminosulfonyl)-2-fluoro-phenyl]-5-(2,5-dimethylbenzyl)- 1 H-1 ,2,4-triazol-3-yl]methyl 2-[2-(nitrooxy)-ethoxy]-ethyl carbonate (170 mg, 76% yield), as a white foam. 1H NMR (400 MHz, CHLOROFORM-d), δ ppm 7.70 - 7.78 (m, 2 H), 7.35 - 7.41 (m, 1 H), 6.95 (d, J=7.8 Hz, 1 H), 6.90 (d, J=7.6 Hz, 1 H), 6.60 (s, 1 H), 5.30 (s, 2 H), 4.99 (s, 2 H), 4.58 - 4.63 (m, 2 H), 4.32 - 4.37 (m, 2 H), 4.07 (s, 2 H), 3.76 - 3.80 (m, 2 H), 3.72 - 3.76 (m, 2 H), 2.16 (s, 3 H), 2.06 (s, 3 H). LC/MS ESI m/z (M+H)+ 568.2. Examples H-2, H-3 were prepared in a similar fashion to that of Example H-1 , and their respective analytical and characterization data are provided in Table 1. Scheme J
Figure imgf000060_0001
J-5
Step 1 : 1 -tert-Butyl 2-Methyl (2S)-4-(Nitrooxy)pyrrolidine-1 ,2-dicarboxylate (j-2)
Figure imgf000060_0002
To a solution of proline alcohol j-1 (840 mg, 3.42 mmol), in CH2CI2 (15 ml), was added tetraethylammonium nitrate (988 mg, 5.14 mmol), and 2,6-di-tert-butyl-4-methylpyridine (1 .05 g, 5.14 mmol). Cooled to -78°C and a solution of trifluoromethanesulfonic anhydride (0.605 ml, 3.60 mmol), in CH2CI2 (2 ml_), was slowly added. After 2 h, the temperature rose to 25°C. The solution was treated with 5% aqueous NaH2PO4 (50 mL), and extracted with CH2CI2 (3 x 75 mL). The combined organic layers were dried with Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (20-35% EtOAc/hexanes), to furnish 1-tert-butyl 2-methyl (2S)-4- (nitrooxy)pyrrolidine-i ,2-dicarboxylate (535 mg, 54% yield), as a white foam.
1H NMR (400 MHz, CHLOROFORM-d), δ ppm 5.48 (s, 1 H), 4.43 - 4.50 (m, 0.4 H), 4.38 (t, J=8.0 Hz, 0.6 H), 3.85 (d, J=3.3 Hz, 2 H), 3.77 (s, 3 H), 2.45 - 2.61 (m, 1 H), 2.28 - 2.41 (m, 1 H), 1.47 (s, 3 H), 1.43 (s, 6 H). LC/MS ESI m/z (M-C4Hg)+ 235.2 and (M-BOC)+ 191.2.
Step 2: 1 -(ferf-Butoxycarbonyl)-4-(nitrooxy)-L-proline (j-3)
Figure imgf000061_0001
LiOH (225 mg, 5.36 mmol), and H2O (3 mL), were added to a solution of the methyl ester (519 mg, 1.79 mmol), in THF (3 mL), and stirred for 2 h. The mixture was acidified to pH~4 using 1 N and 6 N aqueous HCI and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to give 1-(terf-butoxycarbonyl)-4-(nitrooxy)-L- proline (490 mg, 99%), that was carried forward to the next step without further purification. 1H NMR (400 MHz, CHLOROFORM-d), δ ppm 5.48 (s, 1 H), 4.53 (t, J=7.7 Hz, 1 H), 4.42 (t, J=8.0 Hz, 1 H), 3.66 - 3.93 (m, 2 H), 2.34 - 2.81 (m, 2 H), 1.51 (s, 6 H), 1.45 (s, 3 H). LC/MS ESI m/z (M-C4Hg)+ 221.2 and (M-BOC)+ 177.2 Step 3: {[({4-[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-5-(2,5-dimethylbenzyl)-1 H- 1 ,2,4-triazol-1 -yl]-3-fluorophenyl}sulfonamide (j-4)
Figure imgf000062_0001
To a suspension of alcohol a-8 (1 .0Og, 2.56 mmol) was added t-butyldimethylsilyl chloride (425 mg, 2.82 mmol), and imidazole (192 mg, 2.82 mmol). After 16 h, H2O (75 ml_) was added to the mixture and extracted with EtOAc (2 x 100 ml_). The combined organic layers were washed with brine (75 ml_), dried with Na2SO4, filtered, and concentrated under reduced pressure. 4-[3-({[ferf-butyl-dimethyl)-silyl]oxy}-methyl)-5- (2,5-dimethylbenzyl)-1 /-/-1 ,2,4-triazol-1-yl]-3-fluorobenzenesulfonamide (1.30 g, 100%) was isolated as a yellow solid, which was typically used without further purification.
1H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.68 - 7.76 (m, 2 H) 7.34 - 7.39 (m, 1 H) 6.92 - 6.95 (m, 1 H) 6.85 - 6.90 (m, 1 H) 6.60 (s, 1 H) 4.98 (s, 2 H) 4.83 (s, 2 H) 4.08 (s, 2 H) 2.15 (s, 3 H) 2.06 (s, 3 H) 0.93 (s, 9 H) 0.14 (s, 6 H). LC/MS ESI m/z (M+H)+ 505.2.
Step 4: tert-Butyl (2S)-2-{[({4-[3-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-5-(2,5- dimethylbenzyl)-1 H-1 ,2,4-triazol-1 -yl]-3-fluorophenyl}sulfonyl)amino]carbonyl}-4- (nitrooxy)pyrrolidine-i -carboxylate (j-5)
Figure imgf000062_0002
To a solution of the sulfonamide j-4 (300 mg, 0.594 mmol), and proline acid j-3 (164 mg, 0.594 mmol), in DMF (2 mL), was added /-Pr2NEt (0.207 ml_, 1.19 mmol), and HATU
(271 mg, 0.713 mmol). After 3 h, EtOAc (50 mL), was added, then washed with H2O (3 x 30 ml_), and brine (30 ml_), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (80 - 100 % EtOAc/hexanes), to obtain ferf-butyl (2S)-2-{[({4-[3-({[te/t- butyl(dimethyl)silyl]oxy}methyl)-5-(2,5-dimethylbenzyl)-1 /-/-1 ,2,4-triazol-1-yl]-3- fluorophenyl}sulfonyl)amino]carbonyl}-4-(nitrooxy)pyrrolidine-1-carboxylate (409 mg, 90% yield), which was used without further purification.
1H NMR (400 MHz, CHLOROFORM-c/), δ ppm 10.89 (s, 1 H), 7.78 - 7.94 (m, 2 H), 7.34 - 7.41 (m, 1 H), 6.93 (d, J=7.6 Hz, 1 H), 6.88 (d, J=8.3 Hz, 1 H), 6.60 (s, 1 H), 5.43 (s, 1 H), 4.82 (s, 2 H), 4.38 - 4.50 (m, 1 H), 4.07 (s, 2 H), 3.55 - 3.98 (m, 4 H), 2.14 (s, 3 H), 2.05 (s, 3 H), 1.63 (s, 9 H), 0.93 (s, 9 H), 0.13 (s, 6 H). LC/MS ESI m/z (M+H)+ 763.2
Step 5: Λ/-({4-[5-(2,5-Dimethylbenzyl)-3-(hydroxymethyl)-1 H-1 ,2,4-triazoM -yl]-3- fIuorophenyl}sulfonyl)-4-(nitrooxy)-L-prolinamide (J-1 )
Figure imgf000063_0001
To a solution of the silyl-BOC protected substrate j-5 (405, 0.531 mmol), in MeOH (2 ml_), was added dropwise acetyl chloride (0.226 ml_, 3.19 mmol). After 18 h, the mixture was concentrated, and suspended in THF (4 ml_). Triethylamine (0.11 ml_), was added. After 2 h, presumed triethylammonium salt was filtered off and the filtrate was purified by column chromatography (7 - 10 % MeOHZCH2CI2), to give a greenish white solid, which was suspended in CH2CI2, filtered, and washed with CH2CI2 to give Λ/-({4-[5-(2,5- dimethylbenzyl)-3-(hydroxymethyl)-1 /-/-1 ,2,4-triazol-1 -yl]-3-fluorophenyl}sulfonyl)-4- (nitrooxy)-L-prolinamide (158 mg, 53%), as a white solid.
1H NMR (400 MHz, DMSO-d6), δ ppm 8.97 (s, 1 H), 7.71 - 7.81 (m, 2 H), 7.60 - 7.69 (m, J=7.7, 7.7 Hz, 1 H), 6.97 (d, J=7.6 Hz, 1 H), 6.89 (d, J=7.3 Hz, 1 H), 6.64 (s, 1 H), 5.61 (t, J=5.1 Hz, 1 H), 5.35 (t, J=6.2 Hz, 1 H), 4.43 (d, J=6.1 Hz, 2 H), 4.06 (dd, J=10.4, 7.8 Hz, 1 H), 3.97 (s, 2 H), 3.56 - 3.64 (m, 1 H), 3.45 (d, J=13.6 Hz, 1 H), 2.17 - 2.28 (m, 1 H), 2.13 (s, 3 H), 2.03 (s, 3 H). LC/MS ESI m/z (M+H)+ 549.1. Scheme K
Figure imgf000064_0001
Step 1 : [1 -{4-[(Acetylamin enyl}-5-(2,5-dimethylbenzyl)-1 H- 1 ,2,4-triazol-3-yl]methyl 4-(Ni )
Figure imgf000064_0002
To a solution of sulfonamide B-2 (260 mg, 0.499 mmol), in CH2CI2 (2 ml), was added pyridine (0.202 ml_, 2.49 mmol), acetic anhydride (0.141 mL, 1.50 mmol), and DMAP (6.09 mg, 0.050 mmol). After 3 h, the resultant suspension was diluted with EtOAc (20 mL), and washed with H2O (10 mL), 1 N HCI (10 mL), and brine (10 mL). The EtOAc layer was dried with Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography (40 - 65% EtOAc/Hexanes), to provide [1 -{4-[(acetylamino)sulfonyl]-2-fluorophenyl}-5-(2,5-dimethylbenzyl)-1 /-/-1 ,2,4- triazol-3-yl]methyl 4-(nitrooxy)butanoate (198 mg, 71 % yield), as a white solid.
1H NMR (400 MHz, CHLOROFORM-d), δ ppm 8.34 (s, 1 H), 7.92 (dd, J=8.7, 1.89 Hz, 1 H), 7.88 (d, J=8.3 Hz, 1 H), 7.41 (dd, J=8.3, 6.8 Hz, 1 H), 6.94 (d, J=7.6 Hz, 1 H), 6.90 (s, 1 H), 6.61 (s, 1 H), 5.26 (s, 2 H), 4.53 (t, J=6.3 Hz, 2 H), 4.08 (s, 2 H), 2.57 (t, J=7.1 Hz, 2 H), 2.16 (s, 3 H), 2.07 - 2.13 (m, 5 H), 2.05 (s, 3 H). LC/MS ESI m/z (M+H)+ 564.0.
Examples K-2, K3 were prepared in a similar manner to that of K-1 and their respective analytical and characterization data are provided in Table 1. Scheme L
Figure imgf000065_0001
L-1
Step 1 : 2-{[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]methyl} 1 -te/t-Butyl (2S)-4-(nitrooxy)pyrrolidine-1 ,2-dicarboxylate (I-4)
Figure imgf000065_0002
To a solution of the chloride a-9 (300 mg, 0.734 mmol, 1.0 equiv), compound j-3 (243 mg, 0.880 mmol, 1 .20 equiv), crushed K2CO3 (314 mg, 2.27 mmol, 3.1 equiv), and Kl (16 mg, 0.0978 mmol, 0.1 equiv) were added. The reaction mixture was heated up to 6O0C and stirred for 4 h. After cooling to ambient temperature, EtOAc was added and washed with H2O 3x, and brine, dried over Na2SO4, filtered and concentrated. The crude residue was purified by column chromatography (30% to 60% EtOAc/Hexanes) and obtained ester 1-4 (251 mg, 53% yield), which was used without further characterization. LCMS (M+H) +: 649.2.
Step 2: [1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 W-1 ,2,4- triazol-3-yl]methyl 4-(Nitrooxy)-L-prolinate (L-1 )
Figure imgf000066_0001
To a solution of the BOC-protected amine I-4 (251 mg, 0.387 mmol) in CH2CI2 (1.3 mL) was added TFA (0.298 mL, 3.87 mmol). The reaction mixture stirred for 4 h, was quenched with saturated NaHCO3 (30 mL), and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (60 - 100% EtOAc/Hexanes) and 1-[4-(aminosulfonyl)-2-fluorophenyl]- 5-(2,5-dimethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]methyl 4-(nitrooxy)-L-prolinate (75 mg, 35%) was obtained as a white solid.
1H NMR (400 MHz, CHLOROFORM-c/) δ 7.73 - 7.83 (m, 2 H), 7.40 - 7.47 (m, 1 H), 6.95 - 6.99 (m, 1 H), 6.89 - 6.95 (m, 1 H), 6.64 (s, 1 H), 5.42 - 5.47 (m, 1 H), 5.35 - 5.41 (m, 1 H), 4.99 (s, 2 H), 4.79 (t, J=7.6 Hz, 1 H), 4.68 (t, J=7.6 Hz, 1 H), 4.05 (d, J=3.0 Hz, 2 H), 3.95 (d, J=3.8 Hz, 1 H), 2.53 - 2.61 (m, 2 H), 2.18 (s, 3 H), 2.05 (s, 3 H). LCMS (M+H) +: 549.2 Scheme M
Figure imgf000067_0001
m-3 m-4
Figure imgf000067_0002
M-1 m-5 Step 1 : (E,Z)-N'-(4-(5-(2,5-Dimethylbenzyl)-3-(hydroxymethyl)-1 H-1 ,2,4-triazol-1 -yl)- 3-fluorophenylsulfonyl)-N,N-dimethylformamidine (m-1 )
Figure imgf000068_0001
To a solution of the alcohol a-8 (1.63 g, 4.17 mmol) in acetonitrile (50 ml_), was added N1N dimethylformamide dimethyl acetal (1.66 ml_, 12.5 mmol). The solution stirred at ambient temperature for 1 h. The volatiles were removed and the residue triturated in ether to give the product as a white solid (1.8 g, 99 %), which was used without any further purification. LCMS, APCI pos mode M+1 = 446.51
Step 2: (E.ZJ-N'^-IS^.S-DimethylbenzyO-S-formyl-I H-i ^^-triazol-i -yO-S- fluorophenylsulfonyl)-N,N-dimethylformamidine (m-2)
Figure imgf000068_0002
To a solution of the alcohol m-1 (1.87 g, 4.8 mmol) in THF (20 ml.) was added MnO2 (4.1 g, 48.1 mmol). The mixture was stirred at ambient temperature for 8h. The MnO2 was filtered through a bed of Celite and the cake was washed with acetone (3 x 50 ml_). The solvent was removed to give the product as a yellow solid (1.5 g, 71 %), which was used without further purification.
1H NMR (400 MHz, DMSO-d6) δ 2.02 (s, 3 H), 2.09 (s, 3 H), 2.96 (s, 3 H), 3.19 (s, 3 H), 4.15 (s, 2 H), 6.57 (s, 1 H), 6.82 - 6.91 (m, 1 H), 6.92 - 6.99 (m, 1 H), 7.75 - 7.86 (m, 2 H), 7.86 - 7.95 (m, 1 H), 8.29 (s, 1 H), 9.93 (s, 1 H). Step 3: 4-(5-(2,5-Dimethylbenzyl)-3-(1 -hydroxyethyl)-1 H-1 ,2,4-triazol-1 -yl)-3- fluorobenzenesulfonamide (m-3)
Figure imgf000069_0001
To a solution of aldehyde m-2 (200 mg, 0 451 mmol) in THF at -4O0C was added methylmagnesium iodide in diethyl ether (0 600 ml. of 3M in diethyl ether, 1.8 mmol). The reaction was allowed to warm up to ambient temperature over a 2h period. The reaction was quenched with aqueous sat NH4CI (20 ml_) and extracted with ethyl acetate The organic layer was dried over Na2SO4 and evaporated to dryness The product was purified by HPLC using MeCNZH2O/ acetic acid. 1H NMR (400 MHz, METHANOL-d4) δ 1 56 (d, J=6.8 Hz, 3 H), 2.02 (s, 3 H), 2.10 (s, 3 H), 4 12 (s, 2 H) 4 92 (q, J=6 6 Hz, 1 H), 6 54 (s, 1 H), 6 82 - 6 88 (m, 1 H), 6 88 - 6 94 (m, 1 H), 7 51 (t, J=7 8 Hz, 1 H), 7.67 - 7.78 (m, 2 H)
LCMS (APCI, pos Mode) M+1 = 404.1
HRMS Calcd for C19H2IFN4O3S (M+H)+- 404 13 Found: 406.14067
Elemental Anal Calcd for Ci9H2IFN4O3S, C, 56 42; H, 5.23; F, 4.70; N, 13.85, O, 1 1.87, S, 7 93 Found C 54 38, H 5 40, N 13 5, F 4 45, S 7 61.
4-(5-(2,5-Dimethylbenzyl)-3-(1 -hydroxyethyl)-1 H-1 ,2,4-triazoM -yl)-3- fluorobenzenesulfonamide Enantiomers (m-3a) and (m-3b)
The enantiomeric mixture T- 1 was resolved via preparative chiral SFC using a ChiralPak OJ-H, 20% MeOH @ 140 bar, 2.5 mL/min.
1H NMR (400 MHz, MeOD) δ 1 57 (d, J=6 8 Hz, 3 H), 2 02 (s, 3 H), 2 10 (s, 3 H), 4 12 (s, 2 H), 4 92 (q, J=6 6 Hz, 2 H), 6 55 (s, 1 H), 6 85 (s, 1 H), 6 89 - 6 97 (m, 1 H), 7 51 (t, J=7 7 Hz, 1 H), 7 73 (s, 2 H)
The slower eluting enantiomer 1H NMR (400 MHz, MeOD) δ 1 57 (d, J=6 8 Hz, 3 H), 2 02 (s, 3 H), 2 10 (s, 3 H), 4 12 (s, 2 H), 4 92 (q, J=6 6 Hz, 2 H), 6 55 (s, 1 H), 6 85 (s, 1 H), 6 89 - 6 97 (m, 1 H), 7 51 (t, J=7 7 Hz, 1 H), 7 73 (s, 2 H)
Step 4: 1 -[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl [2-(2-chloroethoxy)ethoxy]acetate (m-4) Cl
Figure imgf000070_0001
To 4-{5-(2,5-dιmethylbenzyl)-3-[(1 /?)-1-hydroxyethyl]-1 /-/-1 ,2,4-tπazol-1-yl}-3-fluoro- benzene-sulfonamide (m-3, 0 57 g, 1 41 mmol) and 2-chloropyrιdιne (0 68 mL, 7 2 mmol) in dichloromethane (10 mL) was added [2-(2-chloroethoxy)ethoxy]acetyl chloride (d-3 0 29 g 1 4 mmol) and stirred for 24 h Diluted mixture with EtOAc (70 mL) and partitioned with sat aq NaHCO3 (2 X 50 mL) The organic layer was dried over Na2SO4 then concentrated Purification with silica (M + 25 Biotage cartridge) elution with EtOAc/Hexane (1 1 ), combined purified fractions, and concentrated in vacuo The residue was dissolved in EtOAc (2 mL) and added hexane (2 mL) to afford crystallize product as white solid (0 35 g, 44 8%), which was used without further purification 1 H NMR (400 MHz, CHLOROFORM-c/) δ 7 66 - 7 77 (m, 2 H), 7 31 - 7 39 (m, 1 H), 6 86 - 6 97 (m, 2 H), 6 54 (s, 1 H), 6 03 - 6 20 (m, 1 H), 4 28 - 4 37 (m, 2 H), 4 20 - 4 25 (m, 2 H), 4 18 - 4 20 (m, 2 H), 3 71 - 3 82 (m, 4 H), 3 63 - 3 70 (m, 2 H), 2 14 (s, 3 H), 2 02 - 2 06 (m, 3 H), 1 71 (d, J=6 8 Hz, 3 H) LC/MS ESI m/z (M+H)+, 569 1 Step 5: 1 -[1 -[4-(Aminosulfony!)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl [2-(2-lodoethoxy)ethoxy]acetate (m-5)
Figure imgf000071_0001
Dissolved (1 R)- 1 -[1 -[4-(aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl [2-(2-chloroethoxy)ethoxy]acetate (m-4; 0.35 g, 0.63 mmol) and potassium iodide (0.32 g, 1.89 mmol) in acetone (15 ml_) then warmed to 6O0C for 6Oh. Diluted with EtOAc (70 ml_) partitioned with sat. aq. NaHCO3 (2 X 50 ml_). The organic layer was dried over Na2SO4 and concentrated to afford a clear oil. Purification with silica (M + 25, a Biotage cartridge), elution with EtOAc/Hexane (1 :1 ), then combined purified fractions, concentrated, and dried under high vacuum for 2h to afford a white solid (0.33 g, 79%), which was used without further purification.
1H NMR (400 MHz, CHLOROFORM-c/) δ: 7.62 - 7.77 (m, 2 H), 7.34 (t, 1 H), 6.81 - 6.97 (m, 2 H), 6.54 (s, 1 H), 6.12 (q, J=6.8 Hz, 1 H), 5.16 (bs, 2 H), 4.55 - 4.66 (m, 2 H), 4.17 - 4.25 (m, 2 H), 4.07 (s, 2 H), 3.76 - 3.83 (m, 2 H), 3.66 - 3.76 (m, 4 H), 2.14 (s, 3 H), 2.04 (s, 3 H), 1.71 (d, J=6.6 Hz, 3 H). LC/MS ESI m/z (M+H)+; 661 .0.
Step 4: 1 -[1 -[4-(Aminosulfonyl)-2-fIuorophenyl]-5-(2,5-dimethylbenzyl)-1 H-1 ,2,4- triazol-3-yl]ethyl {2-[2-(Nitrooxy)ethoxy]ethoxy}acetate (M-1)
Figure imgf000071_0002
To a solution of iodo-triazole (1 f?)-1 -[1 -[4-(aminosulfonyl)-2-fluorophenyl]-5-(2,5- dιmethylbenzyl)-1 H-1 ,2,4-triazol-3-yl]ethyl [2-(2-iodoethoxy)ethoxy]acetate (m-5; 0.34 g, 0.53 mmol) in acetonitrile (25 ml) was added silver(l) nitrate (0.25 g, 1.58 mmol) in one portion at 60°C The heterogeneous mixture was allowed to cool to 230C and diluted with sat. aq. NaCI (25 imL) and ethyl acetate (50 ml_). The mixture was vigorously stirred at 230C for 30 min to consume excess silver(l) nitrate. The layers were separated and the aqueous layer was extracted with EtOAc (1 x 30 ml_). The combined organic layers were dried over MgSO4. and concentrated in vacuo. The crude oil was purified by flash chromatography (Biotage, 25 + S) eluting with EtOAc/Hex (60-100% over 10 CV). The purified oil was then azeotroped with dichloromethane (2 x 10 ml_), dissolved in a minimal amount of deionized water, and lyophilized to dryness to provide the desired nitrate ester as a hygroscopic gum (0.23 g, 74%).
1 H NMR (300 MHz, DMSO-J6) δ : 7.73 - 7.87 (m, 3 H), 7.70 (br. s., 2 H), 6.96 (d, J=7.5 Hz, 1 H), 6.88 (d, J=7 7 Hz, 1 H), 6.55 (s, 1 H), 5.95 (q, J=6.5 Hz, 1 H), 4.60 - 4.68 (m, 2 H), 4.15 (d, J=4.3 Hz, 2 H), 4.05 (s, 2 H), 3.67 - 3.73 (m, 2 H), 3.53 - 3.62 (m, 4 H), 2.09 (s, 3 H), 2.02 (s, 3 H), 1 .56 (d, J=6.6 Hz, 3 H).
HRMS (ESI) C25H30FN5O9S (M + H+) m/z: CaIc. 596.1821 , Found: 596.1821.
Scheme N
Figure imgf000073_0001
n-2 n-3
Figure imgf000073_0002
N-1
Step 1 : 4-(5-(2,5-Dimethylbenzyl)-3-formyl-1 H-1 ,2,4-triazoM -yl)-3- fluorobenzenesulfonamide (n-1 )
Figure imgf000073_0003
To a suspension of alcohol a-8 (10.3 g, 26.4 mmol) in CH2CI2 (130 ml_), Dess-Martin periodinane (12.31 g, 29.0 mmol) was added. The reaction mixture was stirred for 3 h and diluted with 5% aq Na2S2O3 (350 ml_) and saturated sodium bicarbonate (400 mL) and extracted with CH2CI2 (3 x 150 mL) The combined organic layers were washed with brine and dried with MgSO4, treated with charcoal, filtered, concentrated under reduced pressure The aldehyde n-1 (9 42 g, 92 % yield) was isolated as an off-white solid and was taken to the next step without further purification
1H NMR (400 MHz, DMSO-c/6) δ 9 94 (s, 1 H) 7 94 - 8 00 (m, 1 H), 7 79 - 7 87 (m, 2 H), 7 73 (s 2 H) 6 96 - 7 00 (m, 1 H), 6 88 - 6 94 (m, 1 H), 6 63 (s, 1 H), 5 76 (s, 1 H), 4 15 (s 2 H) 2 12 (s, 3 H), 2 03 (s, 3 H) LCMS (M+H)+ 389 0
Step 2 4-(5-(2,5-Dιmethylbenzyl)-3-vinyl-1 H-1 ,2,4-triazol-1 -yl)-3- fluorobenzenesulfonamide (n-2)
Figure imgf000074_0001
A solution of sodium hexamethyldisilazane (60 mL of 1 0 M solution in THF) was added dropwise to a suspension of Methyltriphenylphosphonium bromide (26 0 g, 72 8 mmol) in THF (300 mL) After 10 mm, the reaction mixture was cooled to -70°C and a suspension of aldehyde n-1 (9 42 g, 24 3 mmol) in THF (50 mL) was slowly added The mixture was stirred at -7O0C for 10 mm and warmed to ambient temperature and stirred overnight The reaction mixture was poured onto sat aq NH4Cl (400 mL) and EtOAc (200 mL) was added and the phases were separated The aqueous layer was extracted with EtOAc (2 x 200 mL) The combined organic layers were washed with water (200 mL) and brine (200 mL), dried with MgSO4, filtered and concentrated under reduced pressure The crude residue was purified by silica gel plug eluting 50 % heptane/ethyl acetate and obtained alkene n-2 (4 28 g, 46% yield) as a white solid 1H NMR (400 MHz CHLOROFORM-d) δ 7 69 - 7 79 (m, 2 H), 7 33 - 7 40 (m, 1 H), 6 91 - 6 97 (m, 1 H), 6 89 (d, J=I 33 Hz, 1 H), 6 73 (dd, J=17 56, 10 99 Hz, 1 H), 6 59 (s, 1 H), 6 35 (d, J=17 68 Hz 1 H), 5 61 (d, J=1 1 12 Hz, 1 H), 4 96 (s, 2 H), 4 1 1 (s, 2 H), 2 15 (s, 4 H), 2 08 (s 3 H) LCMS (M+H)+ 387 0 Step 3: 4-(5-(2,5-Dimethylbenzyl)-3-(1 ,2-dihydroxyethyl)-1 H-1 ,2,4-triazol-1 -yl)-3- fluorobenzene-sulfonamide (n-3)
Figure imgf000075_0001
To a solution of olefin n-2 (4.38 g, 11.1 mmol) in acetone (180 mL) and water (27 ml_), was added successively NMO (1.43 g, 12.2 mmol) and osmium tetroxide solution (5.1 mL, 2.5 wt % solution in 2-methyl-2-propanol) and stirred at ambient temperature overnight. The reaction mixture was poured onto saturated aq. NH4CI (400 mL) and extracted with EtOAc (3 x 30 mL). The organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was purified by silica gel plug eluting 50 % heptane/ethyl acetate and obtained diol n-3 as a white solid (3.32 g, 71 % yield). 1H NMR (400 MHz, DMSO-Cf6) δ 7.76 - 7.82 (m, 3 H), 7.70 (s, 2 H), 6.93 - 6.98 (m, 1 H), 6.86 - 6.90 (m, 1 H), 6.59 (s, 1 H), 5.43 (d, J=5.6 Hz, 1 H), 4.70 (t, J=5.9 Hz, 1 H), 4.53 - 4.58 (m, 1 H), 4.02 (s, 2 H), 3.59 - 3.70 (m, 2 H), 2.10 (s, 3 H), 2.03 (s, 3 H). LCMS (M-1 )": 419.2.
Step 4: 2-[1 -[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1H-1 ,2,4- triazol-3-yl]-2-hydroxyethyl Nitrate (N-1 )
Figure imgf000075_0002
Dichloromethane (10 mL) and acetic anhydride (2.97 mL. 31.4 mmol) was added to a 50 mL round-bottom flask. The solution was cooled to O0C and fuming nitric acid (1.22 mL, 27.2 mmol) in dichloromethane (10 mL) was added via syringe. The reaction mixture was continued to stir at O0C for 1 h. In a separate 500 mL round-bottom flask, the diol n- 3 (4.40 g, 10.4 mmol), THF (10OmL), dibutyltinoxide (0.05 g, 0.20 mmol), and Et3N (1.45 mL, 10.5 mmol) were added. After stirring at ambient temperature for 30 min, dichloromethane (80 mL) was added followed by the acetic anhydride and fuming nitric acid solution. The reaction mixture was stirred overnight at ambient temperature and then poured onto ice-cold water (80 mL). EtOAc (400 mL) and sat. aq. NaHCO3 (20 mL) were added and partitioned. The aqueous layer was extracted with EtOAc (120 mL). The combined organic layers was washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel plug eluting 50 % heptane/ethyl acetate, then 33% heptane/ethyl acetate to give the nitrate ester N-1 (3.50 g, 72% yield) as a white solid. 1H NMR (400 MHz, DMSO-c/6) δ 7.66 - 7.85 (m, 5 H), 6.93 - 6.99 (m, 1 H), 6.85 - 6.91 (m, 1 H), 6.58 (s, 1 H), 6.17 (d, J=6.1 Hz, 1 H), 4.90 - 4.99 (m, 1 H), 4.76 - 4.86 (m, 2 H), 4.05 (s, 2 H), 2.10 (s, 3 H), 2.02 (s, 3 H). LCMS (M+H)+: 466.2.
Scheme O
Figure imgf000076_0001
Step 1 : tert-Butyl 3-(2-{2-[2-(Nitrooxy)ethoxy]ethoxy}ethoxy)propanoate (o-2)
Figure imgf000077_0001
To a -5O0C solution of tert-butyl 12-hydroxy-4,7,10-trioxadodecanoate (2.50 g, 8.98 mmol) in dichloromethane (45 mL) was added tetraethylamonium nitrate (3.45 g, 18.00 mmol) followed by 2,6-di-tert-butylpyridine (2.98 mL, 13.50 mmol). Trifluoromethanesulfonic anhydride (1.66 mL, 9.88 mmol) in methylene chloride (0.5 mL) was slowly added and the reaction mixture was stirred at -5O0C for 1 h then let warm to ambient temperature over 18h. The reaction mixture was diluted in dichloromethane (45 mL) and 1 N aq. HCI (45 mL). The organic layer was washed with brine (45 mL), dried (MgSO4), and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate-hexane 10-100%) to give the title compound (2.68 g, 92%) as a colorless oil. 1H NMR (300 MHz, DMSO- d6) δ 1.41 (s, 9 H), 2.43 (t, J=6.2 Hz, 2 H), 3.48 - 3.56 (m, 8 H), 3.60 (t, J=6.2 Hz, 2 H), 3.68 - 3.77 (m, 2 H), 4.60 - 4.73 (m, 2 H). HRMS (TOF): calcd for Ci3H26NO8 [MH]+: 324.16529, found: 324.16601.
Anal. Calcd for Ci3H25NO8: C, 48.29; H, 7.79; N, 4.33. Found: C, 48.21 ; H, 7.96; N, 4.39.
Step 2: 3-(2-{2-[2-(Nitrooxy)ethoxy]ethoxy}ethoxy)propanoic Acid (o-3)
ONO2
O-
HO
To a O0C solution of o-2 (1.O g , 3.1 mmol) in dichloromethane (7.5 mL) was added trifluoroacetic acid (7.5 mL). The reaction mixture was stirred at O0C to ambient temperature over 3h. The mixture was diluted with toluene (2 mL) and concentrated under reduced pressure to give the title compound (0.87 g, 100%) as a colorless oil. 1H NMR (300 MHz, DMSO- Gf6) δ 2.46 (t, J=6.3 Hz, 2 H), 3.49 - 3.58 (m, 8 H), 3.62 (t, J=6.4 Hz, 2 H), 3.70 - 3.76 (m, 2 H), 4.59 - 4.73 (m, 2 H). LC/MS (ESI) m/z 268 1 [MH]+
HRMS (TOF) calcd for C9H18NO8 [MH]+ 268 10269, found 268 10435
Step 3. {1 -[4-(Amιnosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-124- trιazol-3-yl}methyl 3-(2-{2-[2-(Nιtrooxy)ethoxy]ethoxy}ethoxy)propanoate (0-1)
Figure imgf000078_0001
To a solution of a-9 (323 mg 0 790 mmol) and o-3 (21 1 mg, 0 790 mmol) in DMSO (4 ml_) was added cesium carbonate (283 mg, 0 869 mmol) The reaction mixture was stirred at ambient temperature for 18h, then at 5O0C for 1 h The reaction mixture was diluted in ethyl acetate (15 mL) and water (5 ml_) The organic layer was washed with water (5 mL), dried (MgSO4) and concentrated under reduced pressure
The residue was purified by column chromatography (ethyl acetate-hexane, 25-100%) to yield the title product (290 mg, 57%) as a colorless oil
1H NMR (300 MHz, DMSO- d6) δ 2 05 (s, 3 H), 2 13 (s, 3 H), 2 62 (t, J=6 1 Hz, 2 H), 3 48 - 3 57 (m, 8 H), 3 66 (t, J=6 1 Hz, 2 H), 3 69 - 3 73 (m, 2 H), 4 07 (s, 2 H), 4 63 - 4 69 (m, 2 H), 5 13 (s, 2 H), 6 62 (s, 1 H), 6 91 (d, J=7 5 Hz, 1 H), 6 98 (d, J=7 5 Hz, 1 H), 7 72 (s, 2 H), 7 77 - 7 92 (m, 3 H) LC/MS (ESI) m/z 640 2 [MH]+
HRMS (TOF) calcd for C27H35FN5Oi0S [MH]+ 640 20832, found 640 20929 Anal Calcd for C27H34FN5O10S^-O 1 H2O C, 50 21 , H, 5 44, N, 10 70 Found C, 50 56, H 5 37, N 10 92 Scheme P
Figure imgf000079_0001
Step 1 : 12,12,13,13-Tetramethyl-3,6,11 -trioxa-12-silatetradec-1 -yl 4- Methylbenzenesulfonate (p-3)
Figure imgf000079_0002
To a solution of 4-(tert-butyldimethylsilyl)oxy-1-butanol (3.2 g, 15.7 mmol) in toluene (24.5 ml_) was added potassium f-butoxide (18.1 ml_, 18.1 mmol, 1 M in THF). After 30 min 2,2'-oxydiethyl ditosylate (5.00 g, 12.1 mmol) was added and the mixture was stirred for 48 h at ambient temperature, then diluted in ethyl acetate (200 mL) and water (50 ml_). The organic layer was washed with brine (50 mL), dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate-hexane, 15-50%) to yield the title product (0.73 g, 14%) as a colorless oil. 1H NMR (300 MHz, DMSO- d6) δ -0.00 (s, 6 H), 0.79 - 0.87 (m, 9 H), 1.39 - 1.52 (m, 4 H), 2.40 (s, 3 H), 3.32 - 3.45 (m, 6 H), 3.52 - 3.58 (m, 4 H), 4.06 - 4.1 1 (m, 2 H), 7.46 (d, J=8.5 Hz, 2 H), 7.76 (d, J=8.3 Hz, 2 H). LC/MS (ESI) m/z 447.2 [MH]+. HRMS (TOF): calcd for C2IH39O6SSi [MH]+: 447.22311 , found: 447.22222.
Anal. Calcd for C2IH38O6SSH-ISH2O: C, 53.25; H, 8.72. Found: C, 53.21 ; H, 8.57.
Step 2: 2-[2-(4-Hydroxybutoxy)ethoxy]ethyl Nitrate (p-4)
O ONO2
To a solution of tosylate p-3 (825 mg, 1.85 mmol) in DMSO (9.25 ml_) was added tetraethylammonium nitrate (710 mg, 3.69 mmol). The reaction mixture was stirred at
750C for 18h. The crude reaction mixture was purified by preparative reverse phase
HPLC (wateπacetonitrile, 85-35%) to yield the title product (0.113 g, 27.4%) as a yellow oil.
1H NMR (300 MHz, DMSO- d6) δ 1.37 - 1 .60 (m, 4 H), 3.38 - 3.44 (m, 4 H), 3.46 - 3.52 (m, 2 H), 3.54 - 3.59 (m, 2 H), 3.70 - 3.76 (m, 2 H), 4.38 (t, J=5.2 Hz, 2 H), 4.65 - 4.70
(m, 2 H).
LC/MS (ESI) m/z 224.0 [MH]+.
HRMS (TOF): calcd for C8H18NO6 [MH]+: 224.1 1286, found: 224.11253.
Anal. Calcd for C8H17NO6-0.2H2O: C, 42.36; H, 7.73; N, 6.18. Found: C, 42.19; H, 7.83; N, 5.95.
Step 3: 4-{2-[2-(Nitrooxy)ethoxy]ethoxy}butanoic Acid (p-5)
HO.
XT ^ ONO2 O
To a solution of alcohol p-4 (95 mg, 0.43 mmol) in a biphasic mixture of water (1.2 mL), CCU (0.81 mL), and acetonitrile (0.81 mL) was added ruthenium trichloride hydrate (2 mg, 0.01 mmol) and sodium metaperiodate (228 mg, 1.06 mmol). The reaction mixture was stirred at ambient temperature for 18h then diluted with brine (5 mL) and extracted with dichloromethane (3x10 mL). The combined organic extracts were dried (MgSO4), and the solvents were removed under reduced pressure. The crude reaction mixture was purified by preparative reverse phase HPLC (wateπacetonitrile, 85-35%) to yield the title product (0.03 g, 30%) as a colorless oil. 1H NMR (300 MHz, DMSO- d6): δ 1.67 - 1.78 (m, 2 H), 2.26 (t, J=7.4 Hz, 2 H), 3.40 (t,
J=6.5 Hz, 2 H), 3.46 - 3.52 (m, 2 H), 3.53 - 3.59 (m, 2 H), 3.70 - 3.76 (m, 2 H), 4.58 -
4.72 (m, 2 H), 12.06 (br. s., 1 H).
LC/MS (ESI) m/z 238.0 [MH]+.
HRMS (TOF): calcd for C8H16NO7 [MH]+: 238.09213, found: 238.09230.
Anal. Calcd for C8H15NO7-CI SH2O: C, 40.05; H, 6.43; N, 5.84. Found: C, 39.97; H, 6.49;
N, 5.70.
Step 4: {1-[4-(Aminosulfonyl)-2-fluorophenyl]-5-(2,5-dimethylbenzyl)-1 H-124- triazol-3-yl}methyl 4-{2-[2-(Nitrooxy)ethoxy]ethoxy}butanoate (P-1 )
Figure imgf000081_0001
To a solution of chloride a-9 (190 mg, 0.464 mmol) and acid p-5 (110 mg, 0.464 mmol) in DMSO (2.3 mL) was added cesium carbonate (159 mg, 0.487 mmol). The reaction mixture was stirred at ambient temperature for 18h, then at 5O0C for 1.5h. The reaction mixture was diluted in ethyl acetate (15 mL) and water (7.5 mL). The organic layer was washed with water (7.5 mL), dried (MgSO4) and concentrated under reduced pressure.
The residue was purified by column chromatography (ethyl acetate-hexane, 25-100%) to yield the title product as a colorless oil (52 mg, 18%).
1H NMR (300 MHz, DMSO- dβ) δ 1.72 - 1.84 (m, 2 H), 2.05 (s, 3 H), 2.13 (s, 3 H), 2.41
(t, J=7.4 Hz, 2 H), 3.38 - 3.43 (m, 2 H), 3.45 - 3.49 (m, 2 H), 3.51 - 3.56 (m, 2 H), 3.69 - 3.74 (m, 2 H), 4.05 - 4.08 (m, 2 H), 4.63 - 4.68 (m, 2 H), 5.13 (s, 2 H), 6.62 (s, 1 H), 6.91
(d, J=7.5 Hz, 1 H), 6.98 (d, J=7.5 Hz, 1 H), 7.72 (s, 2 H), 7.77 - 7.92 (m, 3 H).
LC/MS (ESI) m/z 610.1 [MH]+.
HRMS (TOF): calcd for C26H33FN5O9S [MH]+: 610.19775, found: 610.20081. Table 1
Figure imgf000082_0001
1 (s,
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
- 85 -
Figure imgf000086_0001
While the invention has been illustrated by reference to specific and preferred embodiments, those skilled in the art will recognize that variations and modifications may be made through routine experimentation and practice of the invention. Thus, the invention is intended not to be limited by the foregoing description, but to be defined by the appended claims and their equivalents.

Claims

We Claim:
1. A compound of formula (I):
Figure imgf000087_0001
(I) wherein:
R1 is H, (Ci-Cio)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R . R2 is (Ci-C6)alkyl or NR6R7; R3 is H or halo; each RA, RB, Rc, RD, and RE is independently H, (CrC6)alkyl, (C2-C6)alkenyl, (C2- C6)alkynyl, -OR5, or -C(O)R5; each R5 is independently H, -OH, -NO2, -ONO2, (d-C6)alkyl, (C3-Cio)cycloalkyl,
(CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (C6-Cio)aryl, or (C6-Ci0)heteroaryl, wherein each of said (CrC6)alkyl, (C3-Ci0)cycloalkyl, (Ci-C6)alkoxy, (C3-Cio)cycloalkoxy, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may be the same or different, is independently H, -OH, - o C(O)R8, or -C-R9 ; each R8 is independently (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- Cio)cycloalkyl, (C4-Ci0)heterocycloalkyl, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (C3-Cio)cycloalkyl, (C4-Cio)heterocycloalkyl, (Ce-Cio)aryl, and (Ce- Cio)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-
C6)alkynyl, (C3-C10)cycloalkyl, [(C1-C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m,
(Ci-C6)alkoxy(C1-C6)alkyl, (C3-C10)cycloalkoxy, (Ci-C6)alkyl(NH)nC(=O), -(NH)n(C1- C6)alkoxy, (C4-C10)heterocycloalkyl, (C6-CiO)aryl, or (C6-Ci0)heteroaryl, wherein each of said (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (CrC6)alkoxy, [(Cr C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C3-CiO)CyClOaIkOXy1 (Cr C6)alkyl(NH)nC(=O) -(NH)n(CrC6)alkoxy, (C4-C10)heterocycloalkyl, (C6-C10)aryl, and (C6-Cio)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(CrC10)alkoxy]NO2, [(CrCi0)alkoxy]ONO2, [(CrC6)alkyl]ONO2, or [(CrC6)alkyl]NO2, and m and n are each independently an integer from 1 to 4, or a pharmaceutically acceptable salt or solvate thereof
2 A compound according to claim 1 wherein R1 is -COH, -C(O)NO2,
O O
-C(O)C-C[O(CrC6)alkyl]m-ONO2 -C(O)C-[(CrC6)alkyl]m-ONO2
C(O)C-I(C6 C10)aryl][(d C6)alkyl]-ONO2 _ -C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 _ or
O -C(O)C-[O(CrC6)alkyl]m-ONO2
3 A compound according to claim 1 wherein
Figure imgf000088_0001
, or o
H "
N C — CH3
4 A compound according to claim 1 wherein R3 is selected from Br, Cl, F, and I
5 A compound according to claim 1 wherein each RA, RB, Rc, RD, and RE is independently H or (CrC6)alkyl
6 A compound of formula (Ma)
Figure imgf000089_0001
(Ha) wherein: o
R1 is H, (CrCio)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R9 . R2 is (Ci-C6)alkyl or NR6R7; each R5 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3-Ci0)cycloalkyl,
(CrC6)alkoxy, (C3-C10)cycloalkoxy, (C6-C10)aryl, or (C6-C10)heteroaryl, wherein each of said (Ci-C6)alkyl, (C3-C10)cycloalkyl, (CrC6)alkoxy, (C3-C-ι0)cycloalkoxy, (C6-C10)aryl, and (C6-Cio)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may be the same or different, is independently H, -OH, - C(O)R8, each R8 is independently (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- Cio)cycloalkyl, (C4-Ci0)heterocycloalkyl, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (C3-Ci0)cycloalkyl, (C4-Cio)heterocycloalkyl, (C6-CiO)aryl, and (CQ- Cio)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-
C6)alkynyl, (C3-Ci0)cycloalkyl, [(Ci-Cβ)alkyl(O)]m, -C[0(CrC6)alkyl]m, -[O(CrC6)alkyl]m,
(Ci-C6)alkoxy(Ci-C6)alkyl, (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(C1- C6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-Ci0)aryl, or (C6-C10)heteroaryl, wherein each of said (Ci-C6)alkyl, (C2-C6)aikenyl, (C2-C6)alkynyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, [(Cr
C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C3-Ci0)cycloalkoxy, (Cr
C6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-Ci0)aryl, and
(C6-Cio)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(CrC10)alkoxy]NO2, [(CrC10)alkoxy]ONO2, [(CrC6)alkyl]ONO2, or [(CrC6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
7. A compound according to claim 6 wherein R1 is -COH, -C(O)NO2, o O
I! Il
-C(O)C-C[O(C1-C6)alkyl]m-ONO2 -C(O)C-[(C1-C6)alkyl]m-ONO2
O O
Il
-C(O)C-[(C6-C10)aryl][(C1-Cβ)alkyl]-ONO2 -C(O)C-[(C1-C6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 or
-C(O)C-[O(C1-C6)alkyl]m-ONO2
8. A compound according to claim 6 wherein R is NH2
Figure imgf000090_0001
or o
H I' -N- C-CH3
9. A compound of formula (lib):
Figure imgf000090_0002
(lib) wherein: o Il R1 is H, (Ci-C10)alkyl, -OR5, -C(O)R5, -C(O)OR5, or -C(O)C-R9 .
R2 is (Ci-C6)alkyl or NR6R7; each R5 is independently H1 -OH, -NO2, -ONO2, (CrC6)alkyl, (C3-Ci0)cycloalkyl,
(CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (Cθ-Cio)aryl, or (Ce-Ciojheteroaryl, wherein each of said (CrC6)alkyl, (C3-Cio)cycloalkyl, (CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (C6-Cio)aryl, and (C6-Cio)heteroaryl moieties of said R5 groups is optionally substituted by one or more R9 moieties; each R6 and R7, which may be the same or different, is independently H, -OH, - o
C(O)R8, orc"R ; each R8 is independently (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- Cio)cycloalkyl, (C4-Ci0)heterocycloalkyl, (C6-C10)aryl, or (C6-C-i0)heteroaryl, wherein each of said (C3-Ci0)cycloalkyl, (C4-Cio)heterocycloalkyl, (C6-Ci0)aryl, and (C6- C10)heteroaryl moieties of said R8 groups are optionally substituted by -NO2 or -ONO2; each R9 is independently -NO2, -ONO2, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-
C6)alkynyl, (C3-C10)cycloalkyl, [(CrC6)alkyl(O)]m, -C[O(Ci-C6)alkyl]m, -[O(CrC6)alkyl]m,
(Ci-C6)alkoxy(C1-C6)alkyl, (C3-C10)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(C1- Ce)alkoxy, (C4-C1o)heterocycloalkyl, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, [(C1-
C6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C3-C10)cycloalkoxy, (C1-
C6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-C10)heterocycloalkyl, (C6-Ci0)aryl, and
(C6-Cio)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2,. [(CrC10)alkoxy]Nθ2, [(CrCi0)alkoxy]ONO2, [(CrC6)alkyl]ONO2, or [(CrC6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
10. A compound according to claim 9 wherein R1 is -COH, -C(O)NO2, o o
-C(O)C-C[O(C1-C6)alkyl]m-ONO2 -C(O)C-[(CrC6)alkyl]m-ONO2
O O
-C(O)C-[(C6-C10)aryl][(CrC6)alkyl]-ONO2 -C(O)C-[(CrC6)alkyl](NH)nC(=O)(C1-C6)alkyl-ONO2 Q|.
O -C(O)C-[O(CrC6)alkyl]m-ONO2
1 1 . A compound according to claim 9 wherein R is NH2 ,
Figure imgf000091_0001
o
H » -N- C-CH3
12. A compound of formula (Ilia):
Figure imgf000092_0001
(Ilia) wherein: o R10 is H or C-R13 ;
O
R11 is H, (CrCio)alkyl, -OR12, -C(O)R12, -C(O)OR12, or -C(°)C-R13 ; each R12 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3-Ci0)cycloalkyl, (CrCβJalkoxy, (C3-Ci0)cycloalkoxy, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (CrC6)alkyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, (C3-C10)cycloalkoxy, (C6-Ci0)aryl, and (C6-Ci0)heteroaryl moieties of said R12 groups is optionally substituted by one or more R13 moieties;
R13 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl,
(C3-Cio)cycloalkyl, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (C1-
C6)alkoxy(Ci-C6)alkyl, (C3-Ci0)cycloalkoxy, (CrC6)alkyl(NH)nC(=O), -(NH)n(C1- Ce)alkoxy, (C4-Cio)heterocycloalkyl, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (Ci-Cβ)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, [(C1-
C6)alkyl(O)]m, -C[O(C1-C6)alkyl]m, -[O(d-C6)alkyl]m, (C3-C10)cycloalkoxy, (C1-
C6)alkyl(NH)nC(=O), -(NH)n(Ci-C6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-C10)aryl, and
(C6-C10)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2, [(Ci-C10)alkoxy]NO2, [(Ci-Ci0)alkoxy]ONO2, [(CrC6)alkyl]ONO2, or [(CrC6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof. o
-C— < VONO2
13. A compound according to claim 12 wherein R10 is H, N , or o
- C-CH3
14 A compound according to claim 12 wherein R11 is -COH, -C(O)NO2, o o
-C(O)C-C[O(CrC6)alkyl]m-ONO2 -C(O)C-[(CrC6)alkyl]m-ONO2
-C(O)C-[(C6-C10)aryl][(C1-C6)alkyl]-ONO2 -C(O)C-[(CrC6)alkyl](NH)nC(=O)(CrC6)alkyl-ONO2 Qr
O -C(O)C-[O(CrC6)alkyl]m-ONO2
15. A compound of formula (lllb):
Figure imgf000093_0001
(lllb) wherein: o R10 is H or C-R13 ; o Il
R11 is H, (CrC10)alkyl, -OR12, -C(O)R12, -C(O)OR12, or -C(O)C-R13 . each R12 is independently H, -OH, -NO2, -ONO2, (CrC6)alkyl, (C3-C10)cycloalkyl,
(CrC6)alkoxy, (C3-Cio)cycloalkoxy, (C6-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (Ci-C6)alkyl, (C3-Ci0)cycloalkyl, (CrC6)alkoxy, (C3-Ci0)cycloalkoxy, (C6-C10)aryl, and (C6-Cio)heteroaryl moieties of said R12 groups is optionally substituted by one or more R13 moieties; R13 is independently -NO2, -ONO2, (CrC6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl,
(C3-C10)cycloalkyl, [(CrC6)alkyl(O)]m, -C[O(CrC6)alkyl]m, -[O(CrC6)alkyl]m, (Ci-
C6)alkoxy(CrC6)alkyl, (C3-C10)cycloalkoxy, (CrC6)aikyl(NH)nC(=O), -(NH)n(Cr
C6)alkoxy, (C4-Cio)heterocycloalkyl, (Ce-Cio)aryl, or (C6-Cio)heteroaryl, wherein each of said (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (CrC6)alkoxy, [(Cr
C6)alkyl(O)]m, -C[O(Ci-C6)alkyI]m, -[O(Ci-C6)alkyl]m, (C3-Ci0)cycloalkoxy, (d-
C6)alkyl(NH)nC(=O), -(NH)n(CrC6)alkoxy, (C4-Ci0)heterocycloalkyl, (C6-Ci0)aryl, and
(C6-Ci0)heteroaryl moieties of said R9 groups are optionally substituted by -NO2, -ONO2,
[(Ci-Cio)alkoxy]N02, [(CrC10)alkoxy]ONθ2, [(Ci-C6)alkyl]ONO2, or [(CrC6)alkyl]NO2; and m and n are each independently an integer from 1 to 4; or a pharmaceutically acceptable salt or solvate thereof.
o
-c — ζ ^-ONO2
16. A compound according to claim 15 wherein R10 is H, N , or o M - C-CH3
17 A compound according to claim 15 wherein R11 is -COH, -C(O)NO2, o o
-C(O)C-C[O(CrC6)alkyl]m-ONO2 -C(O)C-[(CrC6)alkyl]m-ONO2
-C(O)C-[(C6-C10)aryl][(C1-C6)alkyl]-ONO2 -C(O)C-[(CrC6)alkyl](NH)nC(=O)(CrC6)alkyl-ONO2 , or
O -C(O)C-[O(CrC6)alkyl]m-ONO2 _
18. A compound selected from the group consisting of:
Figure imgf000094_0001
Figure imgf000095_0001
Chiral
Figure imgf000095_0002
Figure imgf000096_0001
or a pharmaceutically acceptable salt or solvate thereof.
19. The use of a compound according to any one of claims 1 to 18 for the preparation of a medicament for treating glaucoma or ocular hypertension.
20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to any one of claims 1 to 18.
PCT/IB2007/003831 2006-12-15 2007-12-03 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension WO2008075152A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87031406P 2006-12-15 2006-12-15
US60/870,314 2006-12-15
US95476307P 2007-08-08 2007-08-08
US60/954,763 2007-08-08

Publications (1)

Publication Number Publication Date
WO2008075152A1 true WO2008075152A1 (en) 2008-06-26

Family

ID=39365921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003831 WO2008075152A1 (en) 2006-12-15 2007-12-03 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension

Country Status (1)

Country Link
WO (1) WO2008075152A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362894A1 (en) * 2009-11-16 2011-07-14 Ferrer Internacional S.A. Process for preparing 4-nitro-oxy-methyl-benzoic acid
WO2012152438A1 (en) * 2011-05-11 2012-11-15 Nicox S.A. Process for the preparation of nitrate acid ester of organic compounds
CN108383729A (en) * 2018-03-02 2018-08-10 中国海洋石油集团有限公司 A kind of purposes of organic base as catalyst carbonate synthesis dibasic ester
WO2019138362A1 (en) 2018-01-12 2019-07-18 Richter Gedeon Nyrt. Process for the preparation of 4-(4-aminophenyl)morpholin-3-one
CN112566670A (en) * 2018-08-06 2021-03-26 尼科斯股份有限公司 Nitric oxide releasing phosphodiesterase type 5 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681834A (en) * 1995-12-04 1997-10-28 Alcon Laboratories, Inc. Heterocyclic sulfonamides
WO2006042215A1 (en) * 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681834A (en) * 1995-12-04 1997-10-28 Alcon Laboratories, Inc. Heterocyclic sulfonamides
WO2006042215A1 (en) * 2004-10-08 2006-04-20 Janssen Pharmaceutica, N.V. 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362894A1 (en) * 2009-11-16 2011-07-14 Ferrer Internacional S.A. Process for preparing 4-nitro-oxy-methyl-benzoic acid
WO2012152438A1 (en) * 2011-05-11 2012-11-15 Nicox S.A. Process for the preparation of nitrate acid ester of organic compounds
WO2019138362A1 (en) 2018-01-12 2019-07-18 Richter Gedeon Nyrt. Process for the preparation of 4-(4-aminophenyl)morpholin-3-one
CN108383729A (en) * 2018-03-02 2018-08-10 中国海洋石油集团有限公司 A kind of purposes of organic base as catalyst carbonate synthesis dibasic ester
CN112566670A (en) * 2018-08-06 2021-03-26 尼科斯股份有限公司 Nitric oxide releasing phosphodiesterase type 5 inhibitors
US20210322413A1 (en) * 2018-08-06 2021-10-21 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
US11980618B2 (en) * 2018-08-06 2024-05-14 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor

Similar Documents

Publication Publication Date Title
CA2659184C (en) Ep2 agonists
US7910740B2 (en) Modulators of amyloid beta
US20120053165A1 (en) Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
EP2051966A2 (en) Heterocycles useful as inhibitors of carbonic anhydrase
TW201734001A (en) Modulators of ROR-gamma
US20060111416A1 (en) Octahydropyrrolo[3,4-C]pyrrole derivatives
WO2010116270A1 (en) Ep2/4 agonists
ES2670093T3 (en) Thiazole or oxazole P2X7 receptor antagonists substituted
JPWO2007129745A1 (en) Heteroarylamide lower carboxylic acid derivatives
TWI820039B (en) Benzene fused heterocyclic derivatives and pharmaceutical composition comprising the same
CA2741839A1 (en) 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
EP1465872A1 (en) 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
AU2017359773B2 (en) Dihydropyrimidine compound and preparation method and use thereof
US11472813B2 (en) OX2R compounds
CA3125900A1 (en) 15-pgdh inhibitor
PT1801108E (en) Morpholine compounds for the treatment of inflammations
WO2002002542A1 (en) Five-membered-ring compound
JP2013534229A (en) Substituted cyclic carboxamide derivatives and urea derivatives as vanilloid receptor ligands
EP1051415B1 (en) Benzamide derivatives as vasopressin antagonists
WO2008075152A1 (en) 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension
KR100204697B1 (en) Triazolylated tertiary amine compound or salt thereof
BE1009571A3 (en) Piperidine derivatives, method for their production and pharmaceutical compositions containing.
AU2008322960A1 (en) Equilibrative nucleoside transporter ENT1 inhibitors
US20050222223A1 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
JP2009114107A (en) Pharmaceutical composition containing heteroaryl amide lower carboxylic acid derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07848993

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07848993

Country of ref document: EP

Kind code of ref document: A1